[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3821
6. Xu J, Yang Y, Ott J: Survival analysis of microarray expression data by transformation models. Comput Biol Chem; 2005 Apr;29(2):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med.
  • [MeSH-minor] Adenocarcinoma / metabolism. Humans. Lung Neoplasms / metabolism. Proportional Hazards Models

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833436.001).
  • [ISSN] 1476-9271
  • [Journal-full-title] Computational biology and chemistry
  • [ISO-abbreviation] Comput Biol Chem
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / HG00008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


7. Xu H, Wang G, Ma L, Qi F, Liu Y, Yu J, Dai S, Wang E: [Expression of STK15 and its significance in squamous cell carcinoma and adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):259-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of STK15 and its significance in squamous cell carcinoma and adenocarcinoma of the lung].
  • The overexpression of STK15 is significantly associated with carcinogenesis in many tumors, however, its expression and significance in human lung cancer are still unclear.
  • The aim of this study is to investigate the expression of STK15 in squamous cell carcinoma and adenocarcinoma of the lung and to analyze the correlation between STK15 expression and clinicopathological factors.
  • METHODS: The pattern of STK15 protein expression was detected in 44 squamous cell carcinomas, 36 adenocarcinomas and 20 paracancerous lung tissue samples by immunohistochemistry method using anti-STK15 antibody.
  • The relative quantity of STK15 protein expression was detected by Western blot, and STK15 mRNA expression was detected by RT-PCR in 40 fresh lung cancer samples and corresponding paracancerous lung tissues.
  • RESULTS: Positive expression rate of STK15 protein was 68.75% (55/80) in lung cancer tissues and 0% in paracancerous controls (P < 0.001).
  • STK15 expression was significantly related to differentiation grade of lung cancer (P=0.011), but not to histological classification, TNM stages or lymphatic metastasis (P > 0.05).
  • The relative expression levels of STK15 protein (P < 0.001 ) and STK15 mRNA (P < 0.001) in lung cancer tissues were both significantly higher than those of corresponding paracancerous lung tissues.
  • CONCLUSIONS: The expression of STK15 protein and STK15 mRNA is significantly higher in lung cancer tissues than that in paracancerous lung tissues.
  • The expression of STK15 correlates with differentiation of lung cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172157.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Dacic S: EGFR assays in lung cancer. Adv Anat Pathol; 2008 Jul;15(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR assays in lung cancer.
  • The development of small-molecule inhibitors of the epidermal growth factor receptor (EGFR) resulted in new therapeutic options for patients with advanced lung cancer.
  • It was clear from the experience with targeted therapy for breast cancer that a new standardized assay procedure for assessing and predicting the effects of therapeutic agents must be developed.
  • This observation revolutionized understanding of EGFR in lung carcinogenesis and resulted in numerous retrospective studies that correlated patient's response and molecular profile of the lung adenocarcinoma.
  • [MeSH-major] Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Prognosis


9. Takigawa N, Takeuchi M, Shibayama T, Yoshida I, Kawata N, Tada A, Ueoka H, Takahashi K: Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin. Anticancer Res; 2005 May-Jun;25(3c):2579-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin.
  • There are few reports describing simultaneous occurrence of acute leukemia and lung cancer.
  • We describe here an 83-year-old woman who simultaneously developed advanced adenocarcinoma of the lung and acute myeloid leukemia.
  • This combination could be safely administered in the elderly patient with poor performance status and was effective for both lung cancer and acute myeloid leukemia.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Frail Elderly. Leukemia, Myeloid / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy


10. Petibois C, Drogat B, Bikfalvi A, Déléris G, Moenner M: Histological mapping of biochemical changes in solid tumors by FT-IR spectral imaging. FEBS Lett; 2007 Nov 27;581(28):5469-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metabolic parameters of human lung A549/8 adenocarcinoma and U87 glioma cells were compared under stress conditions in culture along with tumor progression after cell implantation onto the chick embryo chorio-allantoic membrane.
  • In cell culture, glucose consumption and lactic acid release were higher in U87 cells.
  • Therefore, FT-IR imaging allows detecting subtle chemical changes in tumors, which might be useful for diagnosis.
  • [MeSH-minor] Cell Hypoxia / drug effects. Cell Line, Tumor. Glucose / pharmacology. Humans. Neoplasm Transplantation

  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983600.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] IY9XDZ35W2 / Glucose
  •  go-up   go-down


11. Baruch AC, Steinbronn K, Sobonya R: Pulmonary adenocarcinomas associated with rheumatoid nodules: a case report and review of the literature. Arch Pathol Lab Med; 2005 Jan;129(1):104-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinomas associated with rheumatoid nodules: a case report and review of the literature.
  • Necrobiotic lung nodules and primary lung carcinoma both occur with some frequency in patients with rheumatoid arthritis; however, few reports exist of a primary lung carcinoma occurring within a rheumatoid nodule.
  • We report a case of a 62-year-old woman with multiple pulmonary nodules discovered incidentally by computed tomography.
  • Immunohistochemical staining supported the diagnosis of both tumors as primary lung carcinomas.
  • Our literature search revealed only 2 other reported cases of adenocarcinoma occurring in association with a rheumatoid nodule; these cases, as well as the association between rheumatoid disease and malignancy, are briefly reviewed.
  • [MeSH-major] Adenocarcinoma / etiology. Lung Diseases / complications. Lung Neoplasms / etiology. Rheumatoid Nodule / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628888.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wang Z, Dai T, Zhan F, Zeng X, Yang Y: [The role of the K+ channel in the inhibition of the human lung adenocarcinoma cell proliferation by rmhTNF]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):399-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of the K+ channel in the inhibition of the human lung adenocarcinoma cell proliferation by rmhTNF].
  • The aim of this study is to investigate the electrophysiological properties of human lung adenocarcinoma cell line A-549 and the role of K+ channel in inhibition of cell proliferation by the recombinant mutant human tumor necrosis factor (rmhTNF).
  • METHODS: Ionic currents were recorded using the whole-cell patch clamp recording technique.
  • The cell cycle and apoptosis rates of the carcinoma cells were measured by flow cytometric analysis (FCM).
  • RESULTS: Whole-cell patch clamp recording revealed a voltage-gated K+ current in A-549 cells, which could be blocked by the K+ channel blocker, TEA and CsCl.
  • The rmhTNF inhibited the cell cycle shifting from G1 phase to S phase and promoted apoptosis as determined by FCM analysis.
  • CONCLUSIONS: rmhTNF exerts its cytotoxic effects on A-549 cells through inhibiting cell cycle shifting and inducing apoptosis.
  • The K+ channels on the A-549 cell membrane can be blocked by rmhTNF partly, and the effect of inhibiting proliferation and activating apoptosis on A-549 cells is a result of depression of the K+ channel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176458.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC: Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia; 2009 Aug;11(8):763-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.
  • A HIC1-SIRT1-p53 circular loop in which hypermethylation in cancer 1 (HIC1) represses the transcription of SIRT1 that deacetylates and inactivates p53 thus leading to HIC1 inactivation has been identified in cell and animal models.
  • However, the alteration and prognostic effects of HIC1-SIRT1-p53 circular loop have never been demonstrated in human cancer patients.
  • We examine the HIC1-SIRT1-p53 alterations in 118 lung cancer patients to define their etiological roles in tumorigenesis.
  • We found that patients with lung squamous cell carcinoma with low p53 acetylation and SIRT1 expression mostly showed low HIC1 expression, confirming deregulation of HIC1-SIRT1-p53 circular loop in the clinical model.
  • Interestingly, the expression of deleted in breast cancer 1 (DBC1), which blocks the interaction between SIRT1 deacetylase and p53, led to acetylated p53 in patients with lung adenocarcinoma.
  • Importantly, lung cancer patients with altered HIC1-SIRT1-p53 circular regulation showed poor prognosis.
  • Our data show the first valid clinical evidence of the deregulation of HIC1-SIRT1-p53 loop in lung tumorigenesis and prognosis.
  • Distinct status of p53 acetylation/deacetylation and HIC1 alteration mechanism result from different SIRT1-DBC1 control and epigenetic alteration in lung squamous cell carcinoma and lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Kruppel-Like Transcription Factors / genetics. Lung Neoplasms / genetics. Sirtuins / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Nov 16;408(6810):377-81 [11099047.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):26-33 [18723112.001]
  • [Cites] Eur J Cancer Prev. 2001 Jun;10(3):213-26 [11432708.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Cell. 2001 Dec 28;107(7):815-8 [11779456.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3794-7 [12097291.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):38-54 [12482959.001]
  • [Cites] Trends Biochem Sci. 2003 Jan;28(1):41-8 [12517451.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):197-202 [12539045.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38313-24 [15231840.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):387-98 [15488761.001]
  • [Cites] Nat Med. 1995 Jun;1(6):570-7 [7585125.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):328-33 [9443413.001]
  • [Cites] Oncogene. 1998 Apr 23;16(16):2159-64 [9572497.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):154-64 [15625370.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):75-81 [15837543.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):241-7 [15900585.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2030-9 [16301995.001]
  • [Cites] PLoS Genet. 2006 Mar;2(3):e40 [16596166.001]
  • [Cites] EMBO J. 2006 Jun 7;25(11):2326-37 [16724116.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):2913-21 [17079682.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):21-9 [17624472.001]
  • [Cites] Nature. 2008 Jan 31;451(7178):583-6 [18235501.001]
  • [Cites] Nature. 2008 Jan 31;451(7178):587-90 [18235502.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):332-9 [17931740.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2613-25 [17982487.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3078-89 [11073960.001]
  • (PMID = 19649206.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  • [Other-IDs] NLM/ PMC2713589
  •  go-up   go-down


1
Advertisement
4. Zhu NL, Li C, Huang HH, Sebald M, Londhe VA, Heisterkamp N, Warburton D, Bellusci S, Minoo P: TNF-alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells. Gene; 2007 May 15;393(1-2):70-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells.
  • TNF-alpha reduced Bmp4 mRNA in lung adenocarcinoma A549 cells and repressed transcriptional activity of the human Bmp4 promoter in a dose-dependent manner.
  • In vivo, TNF-alpha inhibited branching morphogenesis and LacZ gene expression in Bmp4-lacz transgenic lungs.
  • These findings provide a mechanistic paradigm for interactions between mediators of inflammation and morphogenesis with relevant implications for normal lung development and pathogenesis of disease.
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Lung / cytology. Lung / metabolism. Transcription, Genetic / drug effects. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Animals. Base Pairing / genetics. Base Sequence. Binding Sites. Bone Morphogenetic Protein 4. Cell Line, Tumor. Enhancer Elements, Genetic / genetics. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Molecular Sequence Data. NF-kappa B / metabolism. Promoter Regions, Genetic / genetics. Protein Binding / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sequence Deletion. Transcription Factor RelA / metabolism

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 1;18(45):6163-71 [10557108.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6850-60 [16326864.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L806-14 [11053014.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38399-408 [12161428.001]
  • [Cites] Nat Rev Immunol. 2003 Sep;3(9):745-56 [12949498.001]
  • [Cites] Cell. 1988 Dec 2;55(5):887-98 [3142690.001]
  • [Cites] Science. 1988 Dec 16;242(4885):1528-34 [3201241.001]
  • [Cites] Ciba Found Symp. 1989;144:37-55; discussion 55-64, 92-8 [2673683.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):2189-99 [2005904.001]
  • [Cites] Development. 1991 Feb;111(2):531-42 [1893873.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9292-6 [1718003.001]
  • [Cites] Genomics. 1992 Nov;14(3):759-62 [1427904.001]
  • [Cites] Biochem Biophys Res Commun. 1993 May 14;192(3):1049-56 [8507180.001]
  • [Cites] Cell. 1993 Oct 8;75(1):45-58 [8104708.001]
  • [Cites] EMBO J. 1993 Sep;12(9):3551-8 [8253080.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] EMBO J. 1994 Nov 1;13(21):5015-25 [7957067.001]
  • [Cites] Dev Biol. 1994 Nov;166(1):112-22 [7958439.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):2028-35 [7962549.001]
  • [Cites] Dev Dyn. 1994 Oct;201(2):137-50 [7873786.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):250-9 [7542280.001]
  • [Cites] J Biol Chem. 1995 Nov 24;270(47):28364-73 [7499338.001]
  • [Cites] Nature. 1996 Mar 7;380(6569):37-40 [8598900.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 27;219(3):789-94 [8645259.001]
  • [Cites] Development. 1996 Jun;122(6):1693-702 [8674409.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Curr Opin Genet Dev. 1996 Aug;6(4):432-8 [8791534.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20191-7 [9242696.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1266-74 [9488441.001]
  • [Cites] Immunol Today. 1998 Feb;19(2):80-8 [9509763.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):611-4 [9560158.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):615-8 [9560159.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1084-91 [9661072.001]
  • [Cites] Cardiovasc Res. 1999 Apr;42(1):104-12 [10435001.001]
  • [Cites] Development. 1999 Sep;126(18):4005-15 [10457010.001]
  • [Cites] J Bone Miner Res. 1999 Aug;14(8):1432-41 [10457277.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1178-85 [15321788.001]
  • [Cites] Dev Biol. 2000 Sep 15;225(2):322-38 [10985853.001]
  • (PMID = 17350185.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL060231; United States / NHLBI NIH HHS / HL / R01 HL056590; United States / NHLBI NIH HHS / HL / R01 HL107307
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bmp4 protein, mouse; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Proteins; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS22407; NLM/ PMC1945170
  •  go-up   go-down


15. Russo P, Catassi A, Cesario A, Servent D: Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr Med Chem; 2006;13(29):3493-512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system.
  • One of the earliest descriptions of non-neuronal ACh synthesis was by Morris who reported that ACh was synthesized in the placenta [1]; furthermore, Falugi et al. showed the presence of AChE in human fibrosarcoma cells [2].
  • Afterward, the expression of ACh, AChE, and cholinergic receptors in non-neuronal cells was reported in several studies [3-16].
  • Indeed, recent data reported that SCLC expresses a cholinergic autocrine loop that can regulate cell growth.
  • Such work demonstrates that SCLC cells have a cholinergic phenotype and that ACh exerts as an autocrine growth factor in human lung tumours [16].
  • Moreover, it has been recently reported that nicotine in lung adenocarcinoma A549 cells, potently induces Bad phosphorylation at serine (S)112, S136 and S155 in a mechanism involving activation of MAPKs, ERK1/2, PI3K/AKT and PKA through the linking to alpha7-receptors [9].
  • We have recently reported that human malignant pleural mesothelioma expresses a cholinergic system, involved in cell growth regulation.
  • The involvement of the non-neuronal cholinergic system in lung cancer and mesothelioma appears reasonable and opens up new translational research strategies.
  • [MeSH-major] Lung Neoplasms / drug therapy. Receptors, Cholinergic / metabolism
  • [MeSH-minor] Acetylcholine / physiology. Apoptosis / drug effects. Cell Proliferation / drug effects. Cholinergic Antagonists / pharmacology. Humans. Mesothelioma / drug therapy. Mesothelioma / pathology. Snake Venoms / pharmacology


16. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, Brown EJ: Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res; 2010 Dec 1;70(23):9693-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, consistent with a deficiency in long-term genome maintenance, hypomorphic ATR pathway reduction to 16% of normal levels was synthetic lethal with oncogenic Ras expression in cultured cells.
  • Notably, elevated genomic instability and synthetic lethality following suppression of ATR were not due to accelerated cycling rates in Ras-transformed cells, indicating that these synergistic effects were generated on a per-cell-cycle basis.
  • In contrast to the synthetic lethal effects of hypomorphic ATR suppression, subtle reduction of ATR expression (haploinsufficiency) in combination with endogenous levels of K-ras(G12D) expression elevated the incidence of lung adenocarcinoma, spindle cell sarcoma, and thymic lymphoma in p53 heterozygous mice.
  • These results highlight the importance of the ATR pathway both as a barrier to malignant progression and as a potential target for cancer treatment.

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2009 Oct 5;187(1):15-23 [19805627.001]
  • [Cites] Cancer Cell. 2009 Oct 6;16(4):324-35 [19800577.001]
  • [Cites] Cancer. 2010 Feb 15;116(4):896-902 [20052722.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37 [20694727.001]
  • [Cites] Genes Dev. 2000 Feb 15;14(4):397-402 [10691732.001]
  • [Cites] Genes Dev. 2000 Jun 15;14(12):1448-59 [10859164.001]
  • [Cites] Cell. 2001 Feb 9;104(3):397-408 [11239397.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):553-7 [11484057.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):557-61 [11484058.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7727-30 [11691784.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4095-9 [12124347.001]
  • [Cites] Science. 2002 Jul 26;297(5581):602-6 [12142538.001]
  • [Cites] Cell. 2002 Dec 13;111(6):779-89 [12526805.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):615-28 [12629044.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):216-25 [14993903.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1317-30 [15175263.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3164-74 [15282542.001]
  • [Cites] Science. 1987 Apr 10;236(4798):200-2 [3494308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):5124-8 [8197195.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Mol Cell Biol. 2005 May;25(9):3553-62 [15831461.001]
  • [Cites] Genes Dev. 2005 May 1;19(9):1040-52 [15833913.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7091-5 [16103057.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4381-8 [16732333.001]
  • [Cites] Mol Cell. 2006 Nov 3;24(3):433-43 [17081992.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):34759-67 [16968694.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] DNA Repair (Amst). 2007 Jul 1;6(7):953-66 [17531546.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):445-51 [17597761.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1061-8 [17879369.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):113-26 [18371340.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27 [18594563.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] J Biol Chem. 2009 Feb 27;284(9):5994-6003 [19049966.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3091-6 [19470935.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jul;8(7):547-66 [19568282.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(16):4495-507 [19528227.001]
  • [Cites] Mol Cell. 2009 Dec 11;36(5):743-53 [20005839.001]
  • (PMID = 21098704.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG027376; United States / NCI NIH HHS / CA / R25 CA101871; United States / NIA NIH HHS / AG / R01 AG027376-04S1; United States / NIA NIH HHS / AG / R01 AG027376-04; United States / NIA NIH HHS / AG / AG027376-04; United States / NIA NIH HHS / AG / AG027376-04S1; United States / NCI NIH HHS / CA / R25CA101871; United States / NIA NIH HHS / AG / R01AG027376
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Cell Cycle Proteins; 0 / Tumor Suppressor Protein p53; 094ZI81Y45 / Tamoxifen; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Atr protein, mouse; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS247139; NLM/ PMC3057927
  •  go-up   go-down


17. Galgano MT, Hampton GM, Frierson HF Jr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol; 2006 Jun;19(6):847-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HE4 gene expression was highest in normal human trachea and salivary gland, and to a lesser extent, lung, prostate, pituitary gland, thyroid, and kidney.
  • However, adenocarcinomas of the lung, and occasional breast, transitional cell and pancreatic carcinomas had moderate or high levels of HE4 expression.
  • In addition to consistent positivity in ovarian carcinoma, some pulmonary, endometrial, and breast adenocarcinomas, mesotheliomas, and less often, gastrointestinal, renal and transitional cell carcinomas were also positive.
  • Knowledge of the expression patterns of HE4 in our survey is useful for application in histopathologic diagnosis, and should be taken into consideration in future studies that examine the role of HE4 as a serological tumor biomarker or as a target for gene-based therapy.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607372.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


18. Lau D, Guo L, Liu R, Marik J, Lam K: Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. Lung Cancer; 2006 Jun;52(3):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer.
  • Lung cancer is one of the most common cancers and is the leading cause of cancer death.
  • We wish to identify peptide ligands for unique cell surface receptors of non-small lung cancer with the hope of developing these ligands as diagnostic and therapeutic agents.
  • This library was used to screen for peptides that promoted attachment of lung adenocarcinoma cells employing a 'cell-growth-on-bead' assay.
  • These peptides promoted cell adhesion by targeting integrin alpha3beta1 over-expressed in non-small lung cancer cells.
  • These peptide beads can be applied to capture cancer cells in malignant pleural fluid for purpose of diagnosis of lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Integrin alpha3beta1 / antagonists & inhibitors. Lung Neoplasms / metabolism. Neoplasm Proteins / antagonists & inhibitors. Oligopeptides / pharmacology
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Line, Tumor. Humans. Ligands. Peptide Library

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635537.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24CA100014; United States / NCI NIH HHS / CA / R21CA094519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Integrin alpha3beta1; 0 / Ligands; 0 / Neoplasm Proteins; 0 / Oligopeptides; 0 / Peptide Library
  •  go-up   go-down


19. Ichinokawa M, Hida Y, Kaga K, Kawada M, Niizeki H, Kondo S: A case of primary pulmonary hypertension with pulmonary tumor. Ann Thorac Cardiovasc Surg; 2010 Aug;16(4):270-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary pulmonary hypertension with pulmonary tumor.
  • A 64-year-old female with a 9-year history of primary pulmonary hypertension developed a solid pulmonary tumor.
  • Partial lung resection was planned for diagnosis.
  • Although prostacyclin was increased to 8 ng/kg/min, she did not tolerate the decubitus position and one-lung ventilation, and her pulmonary arterial pressure rose to 110/45 mmHg.
  • While she underwent partial resection under two-lung ventilation in the decubitus position, bleeding occurred from the suture line closed by a linear stapler and was controlled by additional sutures.
  • If pulmonary resection becomes necessary in a similar patient, we will plan a partial resection with the patient in a supine position to prevent elevation of pulmonary arterial pressure.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Hypertension, Pulmonary / complications. Lung Neoplasms / surgery


20. Davini F, Gonfiotti A, Vaggelli L, De Francisci A, Gigli P, Janni A: Thoracoscopic localization techniques for patients with solitary pulmonary nodule: radioguided surgery versus hookwire localization. J Cardiovasc Surg (Torino); 2006 Jun;47(3):355-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracoscopic localization techniques for patients with solitary pulmonary nodule: radioguided surgery versus hookwire localization.
  • AIM: The aim of this study is to compare 2 different methods for localization of peripheral pulmonary lesions requiring thoracoscopic resection: radioguided surgery (still considered an innovative method) and computed tomography-guided hookwire localization.
  • METHODS: Thirty randomized patients (21 males and 9 females), ranging from 21-74 years, average age 56.3 years) with solitary pulmonary nodule (SPN) were enrolled in this prospective study.
  • RESULTS: The frozen section revealed a primitive pulmonary tumor in 13 cases, intestinal adenocarcinoma metastasis in 3 cases and renal cancer metastasis in 1 case.
  • CONCLUSION: On the basis of our experience, the conclusion is drawn that this methods has been proven efficacious in the diagnosis of SPN, and video-assisted thoracoscopy allows for the removal of pulmonary nodules without complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Solitary Pulmonary Nodule / surgery. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760874.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  •  go-up   go-down


21. Cho YJ, Murgu SD, Colt HG: Bronchoscopy for bevacizumab-related hemoptysis. Lung Cancer; 2007 Jun;56(3):465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bevacizumab is the first anti-angiogenic agent inhibiting vascular endothelial growth factor (VEGF) for treatment of patients suffering from cancer.
  • The inhibition of VEGF is a possible mechanism involved in the destruction of normal lung tissue and subsequent hemoptysis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / adverse effects. Bronchoscopy / methods. Hemoptysis / diagnosis. Neoplasms, Unknown Primary / drug therapy. Spinal Neoplasms / drug therapy. Thoracic Vertebrae
  • [MeSH-minor] Angiogenesis Inhibitors / adverse effects. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Mediastinum. Middle Aged. Severity of Illness Index. Vascular Endothelial Growth Factor A

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368626.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


22. Huang N, Lu H, Chang L, Zhang H, Zhang H, Li G: [Resveratrol inhibits EGF-induced invasion of human lung adenocarcinoma A549 cells]. Zhongguo Fei Ai Za Zhi; 2010 Apr;13(4):287-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resveratrol inhibits EGF-induced invasion of human lung adenocarcinoma A549 cells].
  • BACKGROUND AND OBJECTIVE: Invasion and metastasis are the primary causes of death in patients with pulmonary carcinoma.
  • Then, the A549 cells were treated with EGF and non-cytotoxic concentration of Resveratrol.
  • [MeSH-major] Adenocarcinoma. Anticarcinogenic Agents / pharmacology. Epidermal Growth Factor / pharmacology. Lung Neoplasms. Stilbenes / pharmacology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677551.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Stilbenes; 62229-50-9 / Epidermal Growth Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; Q369O8926L / resveratrol
  •  go-up   go-down


23. Bhure UN, Lardinois D, Kalff V, Hany TF, Soltermann A, Seifert B, Steinert HC: Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements. Br J Radiol; 2010 Oct;83(994):841-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements.
  • Accurate determination of tumour size in lung adenocarcinoma with bronchoalveolar features (BAC) is important for the determination of TNM (tumour, nodes, metastasis) scores used in staging, prognosis and therapy response assessment.
  • However, tumour sizes derived using lung window (LW) CT or soft-tissue/mediastinal window (MW) CT often give different results.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2002 Jun;36(3):289-95 [12009240.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Jan;109(1):120-9 [7815787.001]
  • [Cites] Ann Thorac Surg. 2003 May;75(5):1601-5; discussion 1605-6 [12735586.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Chest. 2003 Nov;124(5):1828-33 [14605056.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):17-23 [14716227.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Mar;127(3):857-61 [15001917.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1157-61; discussion 1161-2 [15063225.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6 [15145016.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Radiology. 1996 May;199(2):485-8 [8668800.001]
  • [Cites] Radiology. 1996 Aug;200(2):327-31 [8685321.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):465-9 [10430155.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Dec;26(6):1211-5 [15541986.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3279-87 [15886315.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jul;30(1):160-3 [16723239.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1675-9 [17954084.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1828-32; discussion 1832 [14667592.001]
  • [Cites] Eur Radiol. 1999;9(9):1819-25 [10602957.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Lung Cancer. 2001 Jul;33(1):17-25 [11429192.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Aug;122(2):325-30 [11479506.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):43-8 [11891032.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):49-57 [11891033.001]
  • [Cites] Lung Cancer. 2002 May;36(2):175-82 [11955652.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Nov;124(5):1014-20 [12407387.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):351-60 [12002710.001]
  • (PMID = 20846983.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3473756
  •  go-up   go-down


24. Fukui T, Mitsudomi T: Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg; 2008 Mar;56(3):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.
  • Epidermal growth factor receptor (EGFR) gene mutations are frequent in lung cancer arising in patients of Asian ethnicity, female sex, nonsmokers, and adenocarcinoma histology.
  • Another important issue in clinical practice is the fatal interstitial lung disease (ILD) that can develop in patients with gefitinib treatment, especially Asian patients.
  • A nested case-control study recently conducted in Japan identified some risk factors that cause ILD, including age > or = 55 years, a history of smoking, preexisting ILD, poor performance status, short duration since diagnosis of lung cancer, reduced extent of normal lung on computed tomography, and concurrent cardiac disease.
  • EGFR-TKIs are not universally effective for treating lung cancers but are effective in patients with particular genotypes.
  • Based on this concept, Phase III clinical trials comparing gefitinib monotherapy with standard platinum-based chemotherapy are currently ongoing for patients with EGFR mutations and lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Genes, erbB-1 / genetics. Mutation. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Case-Control Studies. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Incidence. Lung Diseases, Interstitial / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Thorac Oncol. 2007 Jan;2(1):22-8 [17410005.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5764-9 [17020982.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1185-9 [9816286.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1191-6 [17387341.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7854-8 [16912157.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3340-6 [16785471.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):998-1004 [17047648.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2248-55 [17538169.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):734-6 [1310070.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2136; author reply 2136 [15901872.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):190-8 [16850125.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12 (8):2538-44 [16638863.001]
  • (PMID = 18340507.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 37
  •  go-up   go-down


25. Gutiérrez Macías A, Lizarralde Palacios E, Merino Múgica JM, Cabeza García S, Martínez Odriozola P, Miguel de la Villa F: [Bilateral chylothorax in a case of metastatic adenocarcinoma of unknown primary]. An Med Interna; 2006 Apr;23(4):176-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral chylothorax in a case of metastatic adenocarcinoma of unknown primary].
  • [Transliterated title] Quilotórax bilateral en un caso de adenocarcinoma metastásico de primario desconocido.
  • We present a case of bilateral chylothorax and lung carcinomatous lymphangitis.
  • Necropsy showed widespread metastatic adenocarcinoma of unknown primary.
  • From this case, we review the etiology, diagnosis and therapeutic options available in chylothorax.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Chylothorax / etiology. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796411.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Bhattacharya K, Birla R, Northridge D, Zamvar V: Platypnea-orthodeoxia syndrome: a rare complication after right pneumonectomy. Ann Thorac Surg; 2009 Dec;88(6):2018-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein we describe a case of platypnea-orthodeoxia syndrome in a patient who underwent a right pneumonectomy for adenocarcinoma of the lung.
  • [MeSH-major] Foramen Ovale, Patent / etiology. Lung Neoplasms / surgery. Pneumonectomy / adverse effects
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Diagnosis, Differential. Echocardiography, Transesophageal. Embolization, Therapeutic / instrumentation. Humans. Male. Middle Aged. Postoperative Complications. Syndrome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2010 Dec;90(6):2087 [21095382.001]
  • (PMID = 19932284.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Kawakami T, Nabeshima K, Makimoto Y, Hamasaki M, Iwasaki A, Shirakusa T, Iwasaki H: Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors. Mod Pathol; 2007 May;20(5):514-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors.
  • Recently, the stromal invasion grading system was proposed for small adenocarcinomas of < or =2.0 cm.
  • In this study, we investigated whether stromal invasion grading system could be applied to and validated in pT1 adenocarcinomas as the TNM classification is the most universally used system.
  • The study included 120 cases of pT1 lung adenocarcinomas, of which 81 (68%) cases were stromal invasion grade 3.
  • Thus, the stromal invasion grading system is reproducible and correlates with prognosis even in pT1 lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334347.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Panduri V, Liu G, Surapureddi S, Kondapalli J, Soberanes S, de Souza-Pinto NC, Bohr VA, Budinger GR, Schumacker PT, Weitzman SA, Kamp DW: Role of mitochondrial hOGG1 and aconitase in oxidant-induced lung epithelial cell apoptosis. Free Radic Biol Med; 2009 Sep 15;47(6):750-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of mitochondrial hOGG1 and aconitase in oxidant-induced lung epithelial cell apoptosis.
  • We report here that overexpression of mitochondria-targeted human alpha-hOgg1 (mt-hOgg1) in human lung adenocarcinoma cells with some alveolar epithelial cell characteristics (A549 cells) prevents oxidant-induced mitochondrial dysfunction and apoptosis by preserving mitochondrial aconitase.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19524665.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL35440; United States / NIEHS NIH HHS / ES / R01 ES013995; United States / NHLBI NIH HHS / HL / K08 HL067835; United States / NIEHS NIH HHS / ES / R01 ES013995-03; United States / NHLBI NIH HHS / HL / R01 HL035440; United States / NHLBI NIH HHS / HL / HL67835-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mutant Proteins; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 3.4.22.- / Caspase 9; EC 4.2.1.3 / Aconitate Hydratase
  • [Other-IDs] NLM/ NIHMS130237; NLM/ PMC4331123
  •  go-up   go-down


29. Banneux N, Bonnet S: [Optic disc metastasis from pulmonary adenocarcinoma]. Bull Soc Belge Ophtalmol; 2007;(305):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optic disc metastasis from pulmonary adenocarcinoma].
  • [Transliterated title] Métastase papillaire d'un adénocarcinome pulmonaire.
  • This man is treated for lung cancer.
  • The diagnosis of an optic disc metastasis was retained according to the ophthalmoscopy and various complementary investigations.
  • DISCUSSION: The optic disc metastasis can occur in a well-known cancer history but may sometimes be the first manifestation of it.
  • Breast and lung cancers are the most common primary neoplasms.
  • The mean age at the time of ocular diagnosis is 55 years.
  • The prognosis is poor because optic nerve metastases occur in advanced metastatic cancer.
  • The mean survival is 13 months after ocular diagnosis.
  • CONCLUSION: Presence of an optic disc lesion may suggest the possibility of a papillary metastasis despite the lack of a cancer history.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Lung Neoplasms / pathology. Optic Nerve Neoplasms / diagnosis. Optic Nerve Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018431.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


30. Sieren JC, Weydert J, Bell A, De Young B, Smith AR, Thiesse J, Namati E, McLennan G: An automated segmentation approach for highlighting the histological complexity of human lung cancer. Ann Biomed Eng; 2010 Dec;38(12):3581-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An automated segmentation approach for highlighting the histological complexity of human lung cancer.
  • Lung cancer nodules, particularly adenocarcinoma, contain a complex intermixing of cellular tissue types: incorporating cancer cells, fibroblastic stromal tissue, and inactive fibrosis.
  • Quantitative proportions and distributions of the various tissue types may be insightful for understanding lung cancer growth, classification, and prognostic factors.
  • However, current methods of histological assessment are qualitative and provide limited opportunity to systematically evaluate the relevance of lung nodule cellular heterogeneity.
  • In this study we present both a manual and an automatic method for segmentation of tissue types in histological sections of resected human lung cancer nodules.
  • The developed, clustering-based, fully automated segmentation approach segments complete lung nodule cross-sectional histology slides in less than 1 min, compared to manual segmentation which requires multiple hours to complete.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):321-31 [14714298.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Biotech Histochem. 1992 Sep;67(5):253-5 [1284404.001]
  • [Cites] N Engl J Med. 1993 Dec 16;329(25):1862-72 [8305063.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):981-5 [9412303.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3279-87 [15886315.001]
  • [Cites] Nat Clin Pract Nephrol. 2005 Nov;1(1):44-54 [16932363.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):494-502 [16930329.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):209-14 [17184664.001]
  • [Cites] Diabetes. 2007 Jul;56(7):1825-33 [17456853.001]
  • [Cites] BMC Med Imaging. 2007;7:7 [17822559.001]
  • [Cites] Anat Rec (Hoboken). 2007 Nov;290(11):1377-87 [17853414.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Apr;135(4):830-6 [18374763.001]
  • [Cites] Int J Clin Exp Pathol. 2009;3(1):98-105 [19918333.001]
  • [Cites] Acad Radiol. 2010 Feb;17(2):169-80 [19926496.001]
  • [Cites] Comput Med Imaging Graph. 2010 Sep;34(6):453-61 [20060681.001]
  • [Cites] Science. 2000 Feb 18;287(5456):1253-8 [10678830.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] Kidney Int. 2003 Jul;64(1):350-5 [12787428.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • (PMID = 20571856.001).
  • [ISSN] 1573-9686
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129022-03; United States / NCI NIH HHS / CA / R01 CA129022; United States / NCI NIH HHS / CA / R01 CA129022-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS251946; NLM/ PMC2996273
  •  go-up   go-down


31. Kurokawa T: [A case of giant prostate carcinoma difficult to diagnose because of absence of urinary difficulty]. Hinyokika Kiyo; 2009 Dec;55(12):769-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A transrectal prostatic biopsy was performed and the histopathological diagnosis was poorly differentiated adenocarcinoma of prostate.
  • The clinical stage was D2 with multiple lung metastases but no bone metastasis.
  • After 3 months of multiple androgen blockade (MAB), the multiple lung metastases disappeared.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Humans. Lung Neoplasms / secondary. Male

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048563.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Zhou WB, Bai M, Jin Y: Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis; 2009 Mar;13(3):381-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the value of vascular endothelial growth factor (VEGF) and endostatin in the differential diagnosis of malignant and tuberculous pleural effusions (PE).
  • METHODS: Effusion samples were collected from 62 patients with malignant PE caused by lung cancer and from 64 patients with tuberculous pleurisy.
  • [MeSH-major] Endostatins / analysis. Pleural Effusion, Malignant / chemistry. Pleural Effusion, Malignant / diagnosis. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adenocarcinoma / complications. Adult. Aged. Carcinoma, Small Cell / complications. Diagnosis, Differential. Female. Humans. Lung Neoplasms / complications. Male. Middle Aged. Pleural Effusion / microbiology. ROC Curve. Sensitivity and Specificity. Tuberculosis, Pulmonary / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275801.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Endostatins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


33. Tirabosco R, Lang-Lazdunski L, Diss TC, Amary MF, Rodriguez-Justo M, Landau D, Lorenzi W, Flanagan AM: Clear cell sarcoma of the mediastinum. Ann Diagn Pathol; 2009 Jun;13(3):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma of the mediastinum.
  • At thoracotomy, the mass was found tightly adherent to the esophageal wall and right lower lobe of the lung.
  • The diagnosis of clear cell sarcoma was supported by demonstrating the presence of an EWS gene rearrangement by fluorescence in situ hybridization.
  • To the best of our knowledge, primary mediastinal clear cell sarcoma has not been previously reported in the literature.
  • We present the case and discuss the differential diagnosis.
  • [MeSH-major] Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. RNA-Binding Protein EWS / genetics. Sarcoma, Clear Cell / genetics. Sarcoma, Clear Cell / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433300.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


34. Amos CI, Gorlov IP, Dong Q, Wu X, Zhang H, Lu EY, Scheet P, Greisinger AJ, Mills GB, Spitz MR: Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst; 2010 Aug 04;102(15):1199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study.
  • Genome-wide association studies of white persons with lung cancer have identified a region of extensive linkage disequilibrium on chromosome 15q25.1 that appears to be associated with both risk for lung cancer and smoking dependence.
  • Because studying African American persons, who exhibit lower levels of linkage disequilibrium in this region, may identify additional loci that are associated with lung cancer, we genotyped 34 single-nucleotide polymorphisms (SNPs) in this region (including LOC123688, PSMA4, CHRNA5, CHRNA3, and CHRNB4 genes) in 467 African American patients with lung cancer and 388 frequency-matched African American control subjects.
  • Associations of SNPs in LOC123688 (rs10519203; odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.25 to 2.05, P = .00016), CHRNA5 (rs2036527; OR = 1.67, 95% CI = 1.26 to 2.21, P = .00031), and CHRNA3 (rs1051730; OR = 1.81, 95% CI = 1.26 to 2.59, P = .00137) genes with lung cancer risk reached Bonferroni-corrected levels of statistical significance (all statistical tests were two-sided).
  • The functional A variant of rs1696698 in CHRNA5 had the strongest association with lung cancer (OR = 1.98, 95% CI = 1.25 to 3.11, P = .003).
  • These SNPs were primarily associated with increased risk for lung adenocarcinoma histology and were only weakly associated with smoking phenotypes.
  • Thus, among African American persons, multiple loci in the region of chromosome 15q25.1 appear to be strongly associated with lung cancer risk.
  • [MeSH-major] African Americans / statistics & numerical data. Chromosomes, Human, Pair 15. Lung Neoplasms / epidemiology. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide. Receptors, Nicotinic / genetics
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adult. Aged. Case-Control Studies. Female. Genetic Predisposition to Disease. Humans. Logistic Models. Male. Middle Aged. Nerve Tissue Proteins / genetics. Proteasome Endopeptidase Complex / genetics. Risk Factors. Smoking / adverse effects. Texas / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Jun;22(6):923-8 [11375900.001]
  • [Cites] JAMA. 2004 Dec 22;292(24):2977-83 [15613665.001]
  • [Cites] Nat Genet. 2008 May;40(5):616-22 [18385676.001]
  • [Cites] Biometrics. 1980 Dec;36(4):627-42 [25856832.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 5;100(21):1552-6 [18957677.001]
  • [Cites] J Thorac Oncol. 2009 Oct;4(10):1195-201 [19641473.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):633-7 [18385738.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):638-42 [18385739.001]
  • [Cites] J Natl Cancer Inst. 1986 Feb;76(2):217-22 [3456060.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1701-6 [14534887.001]
  • [Cites] Hum Mol Genet. 2007 Jan 1;16(1):36-49 [17135278.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8531-5 [14679021.001]
  • [Cites] Cancer Detect Prev. 2007;31(1):29-34 [17303347.001]
  • [Cites] Am J Psychiatry. 2008 Sep;165(9):1163-71 [18519524.001]
  • [Cites] PLoS One. 2009;4(2):e4653 [19247474.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5065-72 [19491260.001]
  • [Cites] Cancer Detect Prev. 2008;32(2):101-8 [18639390.001]
  • [Cites] Am J Hum Genet. 2009 Nov;85(5):679-91 [19836008.001]
  • [Cites] J Natl Cancer Inst. 1963 Feb;30:289-312 [13985327.001]
  • [Cites] N Engl J Med. 2006 Jan 26;354(4):333-42 [16436765.001]
  • (PMID = 20554942.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA127219; United States / NCI NIH HHS / CA / P30CA016772; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / T32 CA096520; United States / NCI NIH HHS / CA / CA141716; United States / NCI NIH HHS / CA / R01 CA127219-04; United States / NCI NIH HHS / CA / R01 CA127219; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / R01CA55769; United States / NCI NIH HHS / CA / CA111646; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / R01CA133996
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CHRNA5 protein, human; 0 / CHRNB4 protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nicotinic; 0 / nicotinic receptor subunit alpha3; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC2914761
  •  go-up   go-down


35. Chen MW, Ni L, Zhao XG, Niu XY: [The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell]. Zhongguo Zhong Yao Za Zhi; 2005 Mar;30(5):357-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell].
  • OBJECTIVE: To study the effect of 20( R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins (VEGF,bFGF, MMP-2) in human lung adenocarcinoma cell line A549 and HUVEC304 cell.
  • METHOD: The cell lines of A549 and HUVEC304 were cultured with 20(R)- Rg3.
  • RESULT: The positive rate of VEGF protein in A549 cell decreased significantly as compared with the control group ( P = 0.03).
  • The gray scales of VEGF, Flt, KDT proteins in both A549 cell lines and HUVEC 304 cell lines decreased ( P = 0.05).
  • Gray scale of MMP-2 also decreased in A549 cell lines.
  • The result of differential expressions of genes of A549 cell lines showed that 14 genes were down-regulated and 10 genes were up-regulated.
  • CONCLUSION: The Chinese materia medica of 20( R)-Rg3 can inhibit the expression of angiogenesis factors proteins via several target genes in both tumour cell and vascular endothelial cell.
  • [MeSH-major] Ginsenosides / pharmacology. Lung Neoplasms. Matrix Metalloproteinase 2 / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Endothelial Cells / metabolism. Gene Expression Profiling. Humans. Neovascularization, Pathologic. Oligonucleotide Array Sequence Analysis. Panax / chemistry. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806969.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ginsenosides; 0 / Vascular Endothelial Growth Factor A; 14197-60-5 / ginsenoside Rg3; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


36. Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA: The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers; 2007;23(1-2):5-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of DNA methylation in the development and progression of lung adenocarcinoma.
  • Lung cancer, caused by smoking in approximately 87% of cases, is the leading cause of cancer death in the United States and Western Europe.
  • Adenocarcinoma is now the most common type of lung cancer in men and women in the United States, and the histological subtype most frequently seen in never-smokers and former smokers.
  • The increasing frequency of adenocarcinoma, which occurs more peripherally in the lung, is thought to be at least partially related to modifications in cigarette manufacturing that have led to a change in the depth of smoke inhalation.
  • The rising incidence of lung adenocarcinoma and its lethal nature underline the importance of understanding the development and progression of this disease.
  • Alterations in DNA methylation are recognized as key epigenetic changes in cancer, contributing to chromosomal instability through global hypomethylation, and aberrant gene expression through alterations in the methylation levels at promoter CpG islands.
  • The identification of sequential changes in DNA methylation during progression and metastasis of lung adenocarcinoma, and the elucidation of their interplay with genetic changes, will broaden our molecular understanding of this disease, providing insights that may be applicable to the development of targeted drugs, as well as powerful markers for early detection and patient classification.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325423.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA102247
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 250
  • [Other-IDs] NLM/ PMC3851711
  •  go-up   go-down


37. Huang YJ, Liu SF, Wang CJ, Huang MY: Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer. Lung Cancer; 2008 Mar;59(3):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
  • A 57-year-old male developed an adenocarcinoma lung cancer in November 2003.
  • The targeted therapy gefitinib was prescribed 2 years after diagnosis, producing a very good partial response.
  • [MeSH-major] Brain Neoplasms / secondary. Hematoma, Subdural / etiology. Lung Neoplasms / pathology. Radiodermatitis / etiology


38. Christensen BC, Marsit CJ, Houseman EA, Godleski JJ, Longacker JL, Zheng S, Yeh RF, Wrensch MR, Wiemels JL, Karagas MR, Bueno R, Sugarbaker DJ, Nelson HH, Wiencke JK, Kelsey KT: Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res; 2009 Aug 1;69(15):6315-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.
  • Pathologic differentiation of tissue of origin in tumors found in the lung can be challenging, with differentiation of mesothelioma and lung adenocarcinoma emblematic of this problem.
  • Indeed, proper classification is essential for determination of treatment regimen for these diseases, making accurate and early diagnosis critical.
  • Here, we investigate the potential of epigenetic profiles of lung adenocarcinoma, mesothelioma, and nonmalignant pulmonary tissues (n = 285) as differentiation markers in an analysis of DNA methylation at 1413 autosomal CpG loci associated with 773 cancer-related genes.
  • Random forests classification of CpG methylation of tumors--which splits the data into training and test sets--accurately differentiated mesothelioma from lung adenocarcinoma over 99% of the time (P < 0.0001).
  • In a locus-by-locus comparison of CpG methylation between tumor types, 1266 CpG loci had significantly different methylation between tumors following correction for multiple comparisons (Q < 0.05); 61% had higher methylation in adenocarcinoma.
  • Using the CpG loci with significant differential methylation in a pathway analysis revealed significant enrichment of methylated gene-loci in Cell Cycle Regulation, DNA Damage Response, PTEN Signaling, and Apoptosis Signaling pathways in lung adenocarcinoma when compared with mesothelioma.
  • Methylation profile-based differentiation of lung adenocarcinoma and mesothelioma is highly accurate, informs on the distinct etiologies of these diseases, and holds promise for clinical application.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):227-34 [19118007.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5727-30 [11479207.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):153-60 [12455028.001]
  • [Cites] Cytogenet Genome Res. 2004;105(2-4):325-34 [15237220.001]
  • [Cites] N Engl J Med. 1980 Jul 24;303(4):200-2 [6155613.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5547-51 [7923195.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4910-4 [7585529.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Diagn Cytopathol. 1999 Oct;21(4):253-9 [10495318.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):523-30 [15559059.001]
  • [Cites] PLoS Biol. 2004 Dec;2(12):e405 [15550986.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):193-204 [15639718.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):219-23 [15540210.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):137-44 [15690333.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):108-14 [17220338.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):140-4 [17525624.001]
  • [Cites] Genomics. 2007 Sep;90(3):314-23 [17582736.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):397-401 [18318582.001]
  • [Cites] Mayo Clin Proc. 2008 May;83(5):584-94 [18452692.001]
  • [Cites] Carcinogenesis. 2008 Aug;29(8):1555-9 [18310086.001]
  • [Cites] BMC Bioinformatics. 2008;9:365 [18782434.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3419-24 [11309302.001]
  • (PMID = 19638575.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA126831; United States / NCI NIH HHS / CA / R01 CA078609-10; United States / NCI NIH HHS / CA / CA126939-01A1; United States / NIEHS NIH HHS / ES / R01 ES006717; United States / NIEHS NIH HHS / ES / P30ES00002; United States / NCI NIH HHS / CA / CA078609-10; United States / NIEHS NIH HHS / ES / P30 ES000002; United States / NCI NIH HHS / CA / ES/CA06409; United States / NIEHS NIH HHS / ES / P42ES05947; United States / NCI NIH HHS / CA / R01 CA126831; United States / NCI NIH HHS / CA / R01 CA105274; United States / NCI NIH HHS / CA / R01 CA078609; United States / NCI NIH HHS / CA / R01 CA100679-06A1; United States / NIEHS NIH HHS / ES / P42 ES005947; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA100679-06A1; United States / NCI NIH HHS / CA / R01 CA126939-02; United States / NIEHS NIH HHS / ES / T32ES007155; United States / NCI NIH HHS / CA / R01CA105274; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA126939; United States / NCI NIH HHS / CA / R01 CA100679; United States / NCI NIH HHS / CA / R01CA52689; United States / NCI NIH HHS / CA / R01 CA126939; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA126939-01A1; United States / NCI NIH HHS / CA / CA126939-02; United States / NIEHS NIH HHS / ES / R01ES006717
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 8J337D1HZY / Cytosine
  • [Other-IDs] NLM/ NIHMS120641; NLM/ PMC2755616
  •  go-up   go-down


39. Masala S, Konda D, Massari F, Simonetti G: Sacroplasty and iliac osteoplasty under combined CT and fluoroscopic guidance. Spine (Phila Pa 1976); 2006 Aug 15;31(18):E667-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A 61-year-old man with medically intractable pain from osteolytic lesions of the sacral ala and left iliac alum from pulmonary adenocarcinoma underwent osteoplasty.
  • [MeSH-minor] Adenocarcinoma / secondary. Bone Cements / therapeutic use. Fluoroscopy. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Pain / etiology. Pain / surgery. Polymethyl Methacrylate / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16915083.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements; 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


40. Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Tsuchiya T, Hisada T, Mori M: Forearm muscle metastasis as an initial clinical manifestation of lung cancer. South Med J; 2009 Jan;102(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Forearm muscle metastasis as an initial clinical manifestation of lung cancer.
  • Skeletal muscle metastasis from lung cancer is rare, and the optimal treatment strategy is unknown.
  • A biopsy of the swollen muscle disclosed the presence of pulmonary adenocarcinoma.
  • Skeletal muscle metastasis as a mode of presentation of primary lung cancer is an unusual phenomenon.
  • [MeSH-major] Adenocarcinoma / secondary. Forearm. Lung Neoplasms / pathology. Muscle Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077783.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Xu YH, Zhang GB, Wang JM, Hu HC: B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J; 2010 Sep;31(9):980-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis.
  • OBJECTIVE: To detect the expression of B7-H3 and CD133 in human non-small cell lung cancer (NSCLC) specimens and lung benign lesions, and to evaluate the correlation between the 2 biomarkers and clinicopathologic features.
  • From the 102 patients, 25 adjacent non-cancer samples were verified pathologically as normal tissue (positive group), and 24 benign inflammatory lesion tissues were used as control (negative group).
  • Specimens from 126 participants were stained immunohistochemically using Image-Pro Plus software, and the cell number was measured in each section.
  • RESULTS: Of the 102 specimens, 71 expressed B7-H3, and 51 expressed CD133, higher than that in benign lesions (p<0.001) or non-cancer tissues (p<0.001).
  • B7-H3 expression in squamous cell carcinoma (SCC) was significantly higher than those in adenocarcinoma (p=0.048), while CD133 expression in large cell lung carcinoma was higher than that in SCC (p=0.023).
  • We found that CD133 was related to tumor cell differentiation degree and CD133 expression was negatively correlated with B7-H3 expression.
  • [MeSH-major] Antigens, CD / biosynthesis. Carcinoma, Non-Small-Cell Lung / genetics. Glycoproteins / biosynthesis. Lung Neoplasms / genetics. Receptors, Immunologic / biosynthesis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. B7 Antigens. Biomarkers / metabolism. Case-Control Studies. Female. Humans. Lung / metabolism. Lung / pathology. Lymphocytes, Tumor-Infiltrating / pathology. Male. Middle Aged. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / genetics. Neoplasms, Squamous Cell / pathology. Peptides / genetics. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20844808.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / B7 Antigens; 0 / Biomarkers; 0 / CD276 protein, human; 0 / Glycoproteins; 0 / Peptides; 0 / Receptors, Immunologic
  •  go-up   go-down


42. Criée CP: [Whole-body plethysmography]. Med Klin (Munich); 2010 Sep;105(9):652-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These parameters are essential to assess a restrictive impairment, overinflation of the lungs and airflow obstruction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Airway Obstruction / diagnosis. Dyspnea / etiology. Lung Neoplasms / diagnosis. Lung Volume Measurements. Plethysmography, Whole Body
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878303.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


43. Merrell RT, Mueller PS: 54-Year-old man with shortness of breath, confusion, and thrombocytopenia. Mayo Clin Proc; 2008 Nov;83(11):1271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Bone Marrow Examination. Bone Neoplasms / secondary. Brain Infarction / diagnosis. Confusion / diagnosis. Dyspnea / diagnosis. Echocardiography, Transesophageal. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pulmonary Embolism / diagnosis. Thrombocytopenia / diagnosis. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990326.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Garrido M, Clavero J, Huete A, Sánchez C, Solar A, Alvarez M, Orellana E: Prolonged survival of a woman with lung cancer diagnosed and treated with chemotherapy during pregnancy. Review of cases reported. Lung Cancer; 2008 May;60(2):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of a woman with lung cancer diagnosed and treated with chemotherapy during pregnancy. Review of cases reported.
  • Lung cancer is the most common cause of cancer death in women in the US, diagnosis during pregnancy is rare and has been reported 34 times.
  • We report a case of a 34-year-old woman with stage III locally advanced lung cancer diagnosed during the 27th week of pregnancy.
  • Chest X-ray and thorax MRI revealed a 9cmx7cm mass in the upper right lung lobe.
  • CT guided FNA biopsy indicated adenocarcinoma.
  • Final pathology was reported as an adenocarcinoma of 7.5cmx6.2cm with involvement of 16/30 lymph nodes.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy


45. Lawson MH, Rassl DM, Cummings NM, Russell R, Morjaria JB, Brenton JD, Murphy G, Rintoul RC: Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol; 2010 Jul;5(7):956-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA.
  • INTRODUCTION: There is a clear need to develop a practical approach to obtain high quality RNA for gene expression analysis from lung cancer patients.
  • We systematically investigated whether high quality RNA could be obtained from routine lung cancer diagnostic biopsies to determine the optimum method.
  • METHODS: Extra biopsies were taken at diagnosis from patients later confirmed to have lung cancer.
  • RESULTS: Acceptable RNA for gene expression analysis was extracted from 72% of lung cancer biopsies.
  • CONCLUSION: Banking lung cancer biopsy specimens by storage in an RNA preservative solution will allow use of a broader spectrum of lung cancers for gene expression analysis.
  • We describe a model that makes personalized medicine for lung cancer patients a more practical proposition.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. RNA, Neoplasm / genetics. Tissue Banks

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20512072.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


46. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R: Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol; 2008 Mar;15(3):889-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers.
  • BACKGROUND: To evaluate the prognostic value of folate receptor alpha (FOLR1) and/or reduced folate carrier (RFC1) expression, which are well-characterized folate transporters, in completely resected non-small-cell lung cancer (NSCLC).
  • RESULTS: In adenocarcinoma, the FOLR1 gene expression was downregulated in smokers and male patients (P = 0.006 and P < 0.001, respectively).
  • In squamous cell carcinoma, FOLR1 expression values in patients with pN1-3 was significantly higher than those with pN0 (P = 0.037).
  • CONCLUSIONS: Higher levels of FOLR1 appear to be associated with better prognoses for patients with lung adenocarcinomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carrier Proteins / genetics. Lung Neoplasms / genetics. Receptors, Cell Surface / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181001.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FOLR1 protein, human; 0 / Folate Receptor 1; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  •  go-up   go-down


47. Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang H, Shen J, Zhao RY, Caraway NP, Katz RL, Stass SA, Jiang F: Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res; 2007 Aug 15;67(16):7901-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target.
  • A functional genomic approach integrating microarray and proteomic analyses done in our laboratory has identified 14-3-3zeta as a putative oncogene whose activation was common and driven by its genomic amplification in lung adenocarcinomas.
  • 14-3-3zeta is believed to function in cell signaling, cycle control, and apoptotic death.
  • Following our initial finding, here, we analyzed its expression in lung tumor tissues obtained from 205 patients with various histologic and stage non-small cell lung cancers (NSCLC) using immunohistochemistry and then explored the effects of specific suppression of the gene in vitro and in a xenograft model using small interfering RNA.
  • The increased 14-3-3zeta expression was positively correlated with a more advanced pathologic stage and grade of NSCLCs (P = 0.001 and P = 0.006, respectively) and was associated with overall and cancer-specific survival rates of the patients (P = 0.022 and P = 0.018, respectively).
  • Down-regulation of 14-3-3zeta in lung cancer cells led to a dose-dependent increased sensitivity to cisplatin-induced cell death, which was associated with the inhibition of cell proliferation and increased G2-M arrest and apoptosis.
  • The result was further confirmed in the animal model, which showed that the A549 lung cancer cells with reduced 14-3-3zeta grew significantly slower than the wild-type A549 cells after cisplatin treatment (P = 0.008).
  • [MeSH-major] 14-3-3 Proteins / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cisplatin / pharmacology. Down-Regulation. Female. Humans. Immunohistochemistry. Male. Mice. Mice, Nude. Middle Aged. Prognosis. RNA, Small Interfering / genetics. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699796.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-113707
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / RNA, Small Interfering; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Bolognesi C, Martini F, Tognon M, Filiberti R, Neri M, Perrone E, Landini E, Canessa PA, Ivaldi GP, Betta P, Mutti L, Puntoni R: A molecular epidemiology case control study on pleural malignant mesothelioma. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1741-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A biomonitoring study was carried out to evaluate the micronuclei frequency in PBLs of patients with pleural malignant mesothelioma with respect to lung cancer, healthy, and risk controls as a marker of cancer susceptibility in correlation with the presence of SV40.
  • A significant increased micronuclei frequency was observed in patients with malignant mesothelioma in comparison with all the other groups, the mean micronuclei frequency was double in patients with malignant mesothelioma compared with healthy controls, risk controls, and patients with lung adenocarcinoma (median 11.4 binucleated cells with micronuclei/1,000 binucleated cells versus 6.2, 6.1, and 5.1, respectively).
  • Our data indicate that human T lymphocyte samples carry DNA sequences coding for SV40 large T antigen at low prevalence, both in cancer cases and controls.
  • Evidence of cytogenetic damage revealed as micronuclei frequency in mesothelioma cancer patients could be related to exogenous and endogenous cofactors besides asbestos exposure.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / etiology. Molecular Epidemiology. Pleural Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030111.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


49. Sompradeekul S, Ittimakin S: Clinical characteristics and outcome of thai patients with acute pulmonary embolism. J Med Assoc Thai; 2007 Nov;90 Suppl 2:59-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of thai patients with acute pulmonary embolism.
  • BACKGROUND: The incidence and clinical features of acute pulmonary embolism (APE) in Thailand are unknown.
  • To compare the clinical characteristics of non-massive and massive APE patients.
  • Fisher's exact test was used to compare the categorical data between massive and non-massive APE groups.
  • RESULTS: Seventy-one patients had a confirmed diagnosis of APE, 22 patients were male and 49 were female.
  • Malignancy, especially adenocarcinoma, was the most frequent risk factor (21%).
  • The most frequent radiographic abnormalities noted in the present study were pulmonary parenchymal lesions (23.9%).
  • The most frequent diagnostic test used was ventilation-perfusion lung scan.
  • In the non-survivor group, the author found hypotension and underlying malignancy statistically significant different from the survivor group.
  • [MeSH-major] Pulmonary Embolism / epidemiology

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230426.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


50. Macedo JE, Costa AM, Barbosa IA, Rebelo S, de Moura CS, da Costa LT, Hespanhol V: Genetic alterations in lung cancer: assessing limitations in routine clinical use. Rev Port Pneumol; 2007 Jan-Feb;13(1):9-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations in lung cancer: assessing limitations in routine clinical use.
  • Lung cancer is the most frequent cause of cancer mortality worldwide, responsible for approximately 1.1 million deaths per year.
  • The development of tumour molecular gene- tics carries the promise of altering this state of affairs, as it should lead to a more precise classification of tumours, identify specific molecular targets for therapy and, above all, allow the development of new methods for early diagnosis.
  • Despite numerous studies demonstrating the usefulness of molecular genetic techniques in the study of lung cancer, its routine clinical use in Portugal has, however, been limited.
  • In this study, we used a p53 mutation screen in multi- ple clinical samples from a series of lung cancer patients to attempt to identify the main practical limitations to the integration of molecular genetics in routine clinical practice.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Small Cell / genetics. Lung Neoplasms / genetics. Mutation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315088.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Portugal
  •  go-up   go-down


51. Sabisz M, Skladanowski A: Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle; 2009 Oct 1;8(19):3208-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models.
  • In this study, using an in vitro human tumor model, we show that non-small lung adenocarcinoma A549 cells after treatment with DNA damaging antitumor drugs become permanently growth-arrested as a result of so-called drug-induced premature senescence (pseudo-senescence).
  • However, a small fraction of drug-treated cells escapes pseudo-senescence that leads to re-growth of tumor cell population after drug treatment.
  • We show that this re-growth is associated with the presence of cancer stem cells (CSCs) in lung tumor cell population.
  • We also document that re-growth of CSCs can be greatly delayed if lung tumor cells are treated with drug/caffeine combination that leads to the inhibition of the ATM/ATR pathway and decreased phosphorylation of PKB/Akt at Ser473.
  • We show that in non-treated A549 cells caffeine by itself induces a reversible growth arrest that is associated with increased fraction of so-called side population cells, containing CSCs.
  • These results point to the existence of an unknown, caffeine-sensitive mechanism that controls the number of CSCs in lung tumor cell population.
  • Full characterization of this mechanism may lead to the development of innovative cancer therapies, which are based on small molecular weight inhibitors of CSC differentiation and self-renewal, which mimic caffeine action.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Aging / drug effects. Lung Neoplasms / metabolism. Neoplastic Stem Cells / drug effects. Razoxane / pharmacology
  • [MeSH-minor] 3-Phosphoinositide-Dependent Protein Kinases. Ataxia Telangiectasia Mutated Proteins. Caffeine / pharmacology. Cell Cycle Proteins / metabolism. Cell Line, Tumor. DNA Damage. DNA-Binding Proteins / metabolism. Drug Resistance, Neoplasm. Humans. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CAFFEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738435.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; 3G6A5W338E / Caffeine; 5AR83PR647 / Razoxane; EC 2.7.11.1 / 3-Phosphoinositide-Dependent Protein Kinases; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


52. Langley RR, Fan D, Guo L, Zhang C, Lin Q, Brantley EC, McCarty JH, Fidler IJ: Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int J Oncol; 2009 Oct;35(4):665-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis.
  • Astrocytes play a critical role in maintaining cerebral homeostasis and their dysregulation is thought to contribute to the pathogenesis of several diseases, including brain cancer and metastasis.
  • Similar to the human disease, we found that lung and melanoma metastases in the mouse brain are accompanied by a reactive gliosis.
  • To begin to study the biology of astrocytes and examine how these cells might contribute to metastasis formation and progression in the brain, we generated a conditionally immortal astrocyte cell line from H-2Kb-tsA58 mice.
  • Astrocytes grown in culture expressed glial fibrillary acid protein (GFAP), glutamate receptor 1, and the N-methyl-D-aspartate (NMDA) receptor.
  • Astrocytes grown under permissive conditions (33 degrees C) expressed SV40 large T antigen and had a doubling time of 36 h, whereas expression of SV40 large T antigen was negligible in astrocytes grown at 37 degrees C for 72 h, which coincided with a plateau in cell division.
  • In a co-culture assay with human lung adenocarcinoma cells (PC14-PE6), astrocytes activated programs in the tumor cells that signal for cell division and survival.
  • Hence, the immortalized cell line will be useful for studying the role of astrocytes in disease processes in the brain, such as metastasis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2003 Dec;2(12):973-85 [14654796.001]
  • [Cites] Drug Discov Today. 2003 Oct 15;8(20):944-54 [14554158.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):195-9 [15356633.001]
  • [Cites] J Natl Cancer Inst. 1979 Sep;63(3):541-8 [112311.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3619-26 [2340511.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5096-100 [1711218.001]
  • [Cites] J Neurosci Res. 1992 Aug;32(4):494-506 [1356158.001]
  • [Cites] FASEB J. 1993 Oct;7(13):1226-32 [8405808.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Sep;53(5):492-501 [8083690.001]
  • [Cites] Ann Neurol. 1995 Jul;38(1):73-84 [7611729.001]
  • [Cites] J Neurol Sci. 1995 Dec;134(1-2):26-32 [8747839.001]
  • [Cites] FASEB J. 1997 Nov;11(13):1187-97 [9367354.001]
  • [Cites] Trends Neurosci. 2004 Dec;27(12):735-43 [15541514.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3719-26 [15749911.001]
  • [Cites] Glia. 2005 Jun;50(4):427-34 [15846805.001]
  • [Cites] Science. 2005 May 6;308(5723):778-81 [15879185.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jun;48(3):488-508 [15914254.001]
  • [Cites] Pharmacol Rev. 2005 Jun;57(2):173-85 [15914466.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10794-800 [16322225.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1065-72 [16354589.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):41-53 [16371949.001]
  • [Cites] Neoplasia. 2006 Sep;8(9):747-57 [16984732.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Endocr Rev. 2007 May;28(3):297-321 [17409287.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3279-90 [17496922.001]
  • [Cites] J Anat. 2007 Jun;210(6):651-60 [17504269.001]
  • [Cites] Nat Neurosci. 2007 Nov;10(11):1355-60 [17965655.001]
  • [Cites] Neurosci Res. 1999 Nov;35(2):155-64 [10616919.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):957-65 [10741721.001]
  • [Cites] Acta Neuropathol. 2000 Aug;100(2):138-44 [10963360.001]
  • [Cites] Neurobiol Dis. 2001 Feb;8(1):78-89 [11162242.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] J Anat. 2002 Jun;200(6):629-38 [12162730.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):289-300 [12398893.001]
  • [Cites] J Neurophysiol. 2002 Nov;88(5):2302-10 [12424271.001]
  • [Cites] Nat Neurosci. 2003 Jan;6(1):43-50 [12469126.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2971-6 [12782605.001]
  • [Cites] J Virol. 2003 Oct;77(19):10638-44 [12970448.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3727-30 [15172974.001]
  • (PMID = 19724901.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS059876-02; United States / NCI NIH HHS / CA / P30 CA016672; United States / NINDS NIH HHS / NS / R01 NS059876-03; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA902701; United States / NINDS NIH HHS / NS / R01 NS059876-02S2; United States / NINDS NIH HHS / NS / R01 NS059876-01A2; United States / NINDS NIH HHS / NS / R01 NS059876; United States / NINDS NIH HHS / NS / R01 NS059876-02; United States / NINDS NIH HHS / NS / R01 NS059876-02S1; United States / NINDS NIH HHS / NS / NS059876-03; United States / NINDS NIH HHS / NS / R01 NS059876-04; United States / NINDS NIH HHS / NS / NS059876-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Polyomavirus Transforming; 0 / CD68 antigen, human; 0 / CD68 protein, mouse; 0 / Excitatory Amino Acid Transporter 1; 0 / Excitatory Amino Acid Transporter 2; 0 / Glial Fibrillary Acidic Protein; 0 / H-2 Antigens; 0 / H-2Kb protein, mouse; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Slc1a2 protein, mouse; 0 / Slc1a3 protein, mouse
  • [Other-IDs] NLM/ NIHMS208798; NLM/ PMC2882684
  •  go-up   go-down


53. Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y: Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer; 2010 Oct;70(1):94-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
  • The activation status of signal transduction pathways involving receptor tyrosine kinases and its association with EGFR or KRAS mutations have been widely studied using cancer cell lines, although it is still uncertain in primary tumors.
  • To study the activation status of main components of growth factor-induced pathways, phosphorylated Akt (pAkt), extracellular signal-regulated kinases 1 and 2 (pERK) and other downstream proteins were immunohistochemically examined using surgical samples of 193 primary lung adenocarcinomas.
  • In lung adenocarcinoma, tumors with TTF-1 expression have distinct characteristics regarding mutations, signal protein activation and clinical issues.
  • Moreover, this property was revealed to be important in outcome estimation at any tumor stage, whereas Akt activation is abnormally affected according to the tumor stage regardless of their cell origin.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Genes, erbB-1. Genes, ras. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Receptor Protein-Tyrosine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20117855.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / TTF1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


54. Hanaoka T, Sone S, Takayama F, Hayano T, Yamaguchi S, Okada M: Presence of local pleural adhesion in CT screening-detected small nodule in the lung periphery suggests noncancerous, inflammatory nature of the lesion. Clin Imaging; 2007 Nov-Dec;31(6):385-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of local pleural adhesion in CT screening-detected small nodule in the lung periphery suggests noncancerous, inflammatory nature of the lesion.
  • PURPOSE: Differential diagnosis of small nodules in the lung periphery detected by low-dose chest CT screening is important before surgery.
  • MATERIALS AND METHODS: This study is based on 106 patients (46 men and 60 women, median age: 61.5 years) with 123 CT screening-detected and histologically confirmed nodules smaller than 30 mm in the lung periphery identified between 2002 and 2005 at Azumi General Hospital, Japan.
  • Lesions were classified into three groups according to histological findings: adenocarcinoma, atypical adenomatous hyperplasia (AAH) and inflammatory focal lesions.
  • We examined the visceral pleura during surgery at a location close to lung nodules.
  • RESULTS: The median diameter of resected lung nodules on high-resolution CT (HRCT) was 9.0 mm.
  • Histopathological diagnosis was lung cancer in 69, AAH in 21, other noninflammatory tumours in 6 and inflammatory lesions in 27.
  • LPA was noted more frequently in inflammatory nodules than in cancer nodules (P<.01).
  • This feature allows the discrimination of pulmonary peripheral inflammatory lesion from peripheral small cancer on chest low-dose CT screening.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography. Pleural Diseases / radiography. Tissue Adhesions / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Hyperplasia. Inflammation / pathology. Inflammation / radiography. Male. Middle Aged


55. New York Early Lung Cancer Action Project Investigators: CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project. Radiology; 2007 Apr;243(1):239-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project.
  • PURPOSE: To evaluate prospectively the diagnostic performance of the New York Early Lung Cancer Action Project (NY-ELCAP) regimen in the diagnosis of early lung cancer at baseline and annual repeat computed tomographic (CT) screenings.
  • All 6295 participants were aged 60 years or older, had smoked for at least 10 pack-years, had no prior cancer, had not undergone chest CT in the previous 3 years, and were medically fit to undergo thoracic surgery.
  • The proportion (and 95% exact confidence intervals [CIs]) of subjects with a positive result, as determined by using nodule size; the diagnoses of lung cancer resulting from subsequent work-up; and the distribution by cancer stage and cell type were determined.
  • Of 101 patients in whom the diagnosis of lung cancer resulted from baseline screening and three in whom a diagnosis of lung cancer was prompted by symptoms prior to the first scheduled repeat screening, 95 (91.3%) had no clinical evidence of metastases.
  • Of the 20 patients in whom the diagnosis of lung cancer resulted from annual repeat screening, 17 (85%) showed no evidence of metastases.
  • Of the 134 recommended biopsies, 125 (93.3%) resulted in diagnosis of lung cancer or another malignancy, while none of the 24 biopsies performed outside of the recommendation of the regimen resulted in diagnosis of lung cancer.
  • CONCLUSION: The NY-ELCAP regimen of screening revealed that annual CT screening for lung cancer resulted in identification of a high proportion of patients with early-stage disease.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography. Mass Screening / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Cohort Studies. Early Diagnosis. Female. Humans. Lung / pathology. Lung / radiography. Lymphatic Metastasis. Male. Neoplasm Staging. Positron-Emission Tomography. Prospective Studies. Smoking. Time Factors


56. Sheikh SS, Al-Khatti AA, Amr SS: Metachronus malignant rhabdoid tumor of the ileum and adenocarcinoma of lung: a unique case report. Ann Diagn Pathol; 2008 Feb;12(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronus malignant rhabdoid tumor of the ileum and adenocarcinoma of lung: a unique case report.
  • These poorly differentiated tumors pose a great deal of difficulty in diagnosis as well as in deciding whether they are primary or metastatic in origin because malignant rhabdoid tumors or carcinomas with rhabdoid differentiation of other sites can metastasize to the small intestine.
  • They behave more aggressively than the typical adenocarcinomas of the same location.
  • Five years later, he was found to have a lung mass proved to be adenocarcinoma, exhibiting focal giant cell differentiation without rhabdoid features.
  • [MeSH-major] Adenocarcinoma / pathology. Ileal Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Rhabdoid Tumor / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164418.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Summers RJ, Shehata BM, Bleacher JC, Stockwell C, Rapkin L: Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. J Pediatr Surg; 2010 Nov;45(11):2256-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation.
  • Congenital pulmonary airway malformation (CPAM) is a rare developmental abnormality of the lung that has been associated with the presence of rhabdomyosarcoma, pleuropulmonary blastoma, and most commonly bronchioalveolar carcinoma (BAC) of the lung.
  • Here, we report the case of an 8-year-old patient who developed KRAS mutation positive stage IV mucinous adenocarcinoma of the lung in association with CPAM.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cystic Adenomatoid Malformation of Lung, Congenital / diagnosis. Lung Neoplasms / diagnosis. Precancerous Conditions
  • [MeSH-minor] Bronchoscopy. Child. Diagnosis, Differential. Female. Humans. Pneumonectomy / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21034957.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS: Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer; 2009 Sep;65(3):351-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
  • Good and rapid response to epidermal growth factor tyrosine kinase inhibitor (EGFR TKI) treatment makes this an attractive option for never-smokers with adenocarcinoma of the lung.
  • Between January 2005 and August 2007, 23 Korean never-smoking patients with adenocarcinoma of the lung who had synchronous asymptomatic brain metastasis were consecutively treated with EGFR TKI therapy, either gefitinib 250 mg or erlotinib 150 mg once daily, as first-line treatment after giving informed consent, until disease progression, unacceptable toxicity or patient's refusal.
  • In conclusion, EGFR TKI treatment showed promising antitumor activity against both intracranial and extracranial tumors in chemotherapy-naïve never-smokers with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / drug therapy. Brain Neoplasms / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157632.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


59. Pozzi EC, Altermatt HJ, Rees TD, Bornstein MM: Exophytic mass of the gingiva as the first manifestation of metastatic pulmonary adenocarcinoma. J Periodontol; 2008 Jan;79(1):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic mass of the gingiva as the first manifestation of metastatic pulmonary adenocarcinoma.
  • METHODS: The clinicopathologic features of a gingival metastasis originating from lung adenocarcinoma in a female patient are described.
  • Because the differentiation between carcinoma and sarcoma of spindle cell tumors was difficult, additional immunohistochemical evaluation was performed.
  • Finally, a biopsy of the lungs confirmed a poorly differentiated adenocarcinoma with multiple metastases, including the oral cavity.
  • CONCLUSIONS: An exophytic lesion on the gingiva can be the first sign of metastatic adenocarcinoma to the oral mucosa.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Lung Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-7 / analysis. Mandible. Middle Aged. Nuclear Proteins / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166110.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


60. Goto Y, Hojo M, Takeda Y, Kobayashi N, Kudo K: Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report. Med Oncol; 2010 Sep;27(3):753-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
  • A 77-year-old woman was diagnosed as having advanced non-small cell lung cancer, and was started on treatment with gefitinib.
  • A diagnosis of gefitinib-induced interstitial lung disease was made, and administration of high-dose prednisolone (1 g/day of intravenous methylprednisolone for three consecutive days, followed by oral prednisolone at 50 mg/day) was started.
  • Although progression to respiratory failure could be stopped by the corticosteroid treatment, there was still no improvement in either the lung opacities seen on radiologic imaging, or in the symptoms; moreover, the patient developed corticosteroid-induced myopathy.
  • Thus, it is considered that intravenous cyclophosphamide may be a valid treatment option for gefitinib-induced lung injury.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cyclophosphamide / therapeutic use. Lung Diseases, Interstitial / chemically induced. Methylprednisolone / therapeutic use. Prednisolone / therapeutic use. Quinazolines / adverse effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Asian Continental Ancestry Group. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Evaluation. Drug Therapy, Combination. Female. Genetic Predisposition to Disease. Humans. Infusions, Intravenous. Lung Neoplasms / drug therapy. Muscular Diseases / chemically induced

  • Genetic Alliance. consumer health - Interstitial Lung Disease.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64 [10673212.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):339-42 [12781434.001]
  • [Cites] Respirology. 2006 Mar;11(2):217-20 [16548909.001]
  • [Cites] Respirology. 2006 Jan;11(1):113-6 [16423212.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):137-9 [12531582.001]
  • [Cites] Lung Cancer. 2006 May;52(2):135-40 [16574271.001]
  • [Cites] Thorax. 1989 Apr;44(4):280-8 [2669218.001]
  • [Cites] Drug Saf. 2004;27(14):1081-92 [15554744.001]
  • (PMID = 19653137.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; S65743JHBS / gefitinib; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


61. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M: c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci; 2007 Jul;98(7):1006-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.
  • c-Met is often overexpressed in non-small cell lung cancer, but it remains unsolved whether its overexpression leads to its activation.
  • We used an antibody specific to phospho-c-Met (Tyr1235) to investigate c-Met activation immunohistochemically in 130 surgically resected lung adenocarcinomas.
  • The data suggest that in lung adenocarcinoma tissue, c-Met activation may take place either ligand-dependently or ligand-independently via c-Met overexpression. c-Met activation may play special roles in the papillary subtype and in well differentiated lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Hepatocyte Growth Factor / metabolism. Lung Neoplasms / enzymology. Proto-Oncogene Proteins c-met / metabolism
  • [MeSH-minor] Aged. Cell Differentiation. Enzyme Activation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Phosphoproteins / metabolism. Phosphorylation. Survival Analysis


62. Chijiwa T, Abe Y, Inoue Y, Matsumoto H, Kawai K, Matsuyama M, Miyazaki N, Inoue H, Mukai M, Ueyama Y, Nakamura M: Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. Oncol Rep; 2009 Aug;22(2):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma.
  • Thrombospondin (TSP)-2 is known to be an endogenous negative regulator of vascularization in human cancer.
  • However, it is unclear whether TSP-2 expression is related to neovascularization and prognosis in non-small cell lung cancer.
  • In this study, we quantitatively examined the expression of TSP-2 mRNA by real-time reverse transcription-polymerase chain reaction (RT-PCR) in 102 pulmonary adenocarcinomas.
  • The expression of TSP-2 mRNA in carcinoma was significantly higher than normal lung tissues (p<0.0001, Kruskal-Wallis test).
  • The TSP-2 expression levels of the stage II/III pulmonary carcinomas were significantly increased as compared to those of stage I (p=0.0136, Kruskal-Wallis test).
  • We examined TSP-2 protein localizations in the pulmonary adenocarcinoma overexpressing TSP-2 mRNA.
  • The TSP-2 localizations were categorized in two patterns: cancerous TSP-2 expression pattern (TSP-2 expression in the cancerous cells) and non-cancerous TSP-2 expression pattern (TSP-2 expression in the stromal lymphoid cells).
  • Pulmonary adenocarcinoma patients with cancerous TSP-2 expression pattern showed good prognosis (p=0.0322; Fisher's probability exact test).
  • Pulmonary adenocarcinoma patients with non-cancerous TSP-2 expression pattern showed poor prognosis (p=0.0220; Fisher's probability exact test).
  • Non-cancerous TSP-2 expressions may reflect secondary reactions in the cancerous stroma.
  • The stromal TSP-2 expression is not enough to suppress growth of pulmonary adenocarcinoma, while the cancerous TSP-2 expression directly inhibits growth of the carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Lung Neoplasms / mortality. Thrombospondins / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578767.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Thrombospondins; 0 / thrombospondin 2
  •  go-up   go-down


63. Valdespino-Castillo VE, Ruiz-Jaime A: [Renal cell carcinoma with colon metastases: an infrequent site for metastases]. Cir Cir; 2008 Jul-Aug;76(4):339-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell carcinoma with colon metastases: an infrequent site for metastases].
  • [Transliterated title] Cáncer de riñón con metástasis a colon. Un sitio poco frecuente de metástasis.
  • BACKGROUND: Renal cell carcinoma (RCC) represents approximately 3% of malignant tumors in adults and occurs in a M:F ratio of 1.5:1.0.
  • Clear cell carcinoma is the most frequent histological type, and 30% of renal carcinomas have metastasized at the time of diagnosis.
  • The objective of the present study is to report colon metastasis of clear cell carcinoma that required surgery and chemotherapy.
  • His treatment consisted of cytoreductive radical nephrectomy and interferon because of pulmonary disease.
  • Biopsy reported a clear cell tumor.
  • Pathology report was clear cell carcinoma with involvement of the colon from the mucosa to serosa.
  • CONCLUSIONS: RCC metastases are most frequent in lung, liver, and bone and less frequent in brain, skin, and soft tissue.
  • Metastatic clear cell carcinoma requires surgery and immunotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Carcinoma, Renal Cell / secondary. Colonic Neoplasms / secondary. Kidney Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Colectomy / methods. Combined Modality Therapy. Follow-Up Studies. Gastrointestinal Hemorrhage / etiology. Humans. Immunotherapy. Interferon-alpha / therapeutic use. Lung Neoplasms / secondary. Male. Middle Aged. Nephrectomy / methods. Remission Induction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778546.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


64. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G: Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai); 2010 Mar 15;42(3):224-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion.
  • Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is suggested to be a long (~7 kb) non-coding RNA.
  • To investigate the role of MALAT1 in human cervical cancer progression, we designed and used short hairpin RNA to inhibit MALAT1 expression in CaSki cells and validated its effect on cell proliferation and invasion.
  • Our data demonstrated that MALAT1 was involved in cervical cancer cell growth, cell cycle progression, and invasion through the regulation of gene expression, such as caspase-3, -8, Bax, Bcl-2, and BclxL, suggesting that MALAT1 could have important implications in cervical cancer biology.
  • Our findings illustrate the biological significance of MALAT1 in cervical cancer progression and provide novel evidence that MALAT1 may serve as a therapeutic target in the prevention of human cervical cancer.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Female. Gene Silencing. Humans. Neoplasm Invasiveness


65. Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM, Bigbee WL: Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res; 2010 Dec 3;9(12):6440-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.
  • Targeted glycoproteomics represents an attractive approach for conducting peripheral blood based cancer biomarker discovery due to the well-known altered pattern of protein glycosylation in cancer and the reduced complexity of the resultant glycoproteome.
  • Here we report its application to a set of pooled nonsmall cell lung cancer (NSCLC) case sera (9 adenocarcinoma and 6 squamous cell carcinoma pools from 54 patients) and matched controls pools, including 8 clinical control pools with computed tomography detected nodules but being nonmalignant as determined by biopsy from 54 patients, and 8 matched healthy control pools from 106 cancer-free subjects.
  • The goal of the study is to discover biomarkers that may enable improved early detection and diagnosis of lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Gerontol. 2001 Sep;36(9):1551-63 [11525877.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):660-6 [12754519.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):667-72 [12754521.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Biotechnol Genet Eng Rev. 2003;20:199-244 [14997853.001]
  • [Cites] Curr Opin Chem Biol. 2004 Feb;8(1):66-75 [15036159.001]
  • [Cites] Jpn J Clin Oncol. 1986 Dec;16(4):335-46 [3467106.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):909-16 [2442609.001]
  • [Cites] Radiology. 1996 Dec;201(3):798-802 [8939234.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93 [15632829.001]
  • [Cites] Glycobiology. 2005 May;15(5):447-62 [15616123.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2070-80 [16335952.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):573-88 [16332733.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3938-48 [16767791.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):141-9 [17074749.001]
  • [Cites] Nat Protoc. 2007;2(2):334-9 [17406594.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3475-83 [17705522.001]
  • [Cites] Arch Intern Med. 2007 Nov 26;167(21):2289-95 [18039986.001]
  • [Cites] Proteomics. 2007 Dec;7(23):4292-302 [17963278.001]
  • [Cites] J Proteomics. 2008 Apr 30;71(1):61-70 [18541474.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Nov 1;178(9):956-61 [18635890.001]
  • [Cites] Surg Oncol. 2009 Mar;18(1):15-24 [18619834.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1206-20 [19294700.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:89 [19549343.001]
  • [Cites] Mol Cell Proteomics. 2009 Aug;8(8):1860-77 [19411661.001]
  • [Cites] Methods Mol Biol. 2010;604:273-83 [20013377.001]
  • [Cites] CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119 [20228384.001]
  • [Cites] Cell. 2010 Mar 19;140(6):883-99 [20303878.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • (PMID = 20931982.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090440; United States / NCI NIH HHS / CA / U01 CA084968-10; United States / NCI NIH HHS / CA / P50CA90440; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / P50 CA090440-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycopeptides; 0 / Glycoproteins
  • [Other-IDs] NLM/ NIHMS249067; NLM/ PMC3184639
  •  go-up   go-down


66. Henschke CI, Yankelevitz DF, Miettinen OS, International Early Lung Cancer Action Program Investigators: Computed tomographic screening for lung cancer: the relationship of disease stage to tumor size. Arch Intern Med; 2006 Feb 13;166(3):321-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computed tomographic screening for lung cancer: the relationship of disease stage to tumor size.
  • BACKGROUND: The relationship of lung cancer stage to tumor diameter has been identified as a prognostic indicator.
  • We report on the stage-size relationship of these asymptomatic, latent lung cancer cases diagnosed by computed tomographic screening.
  • METHODS: Baseline and repeat screening of 28 689 people following the International Early Lung Cancer Action Program regimen of screening has resulted in 464 diagnoses of lung cancer.
  • Each case was characterized according to tumor diameter, consistency (solid, part solid, or nonsolid), and the presence or absence of identifiable metastases (N0 M0) at the time of diagnosis, regardless of whether it was delayed.
  • RESULTS: For the 436 non-small cell carcinomas, the percentages of cases with no metastases (N0 M0) were 91%, 83%, 68%, and 55% for the categories 15 mm or less, 16 to 25 mm, 26 to 35 mm, and 36 mm or greater, respectively.
  • For the 28 small cell carcinomas, the percentages of N0 M0 cases were 67% and 23% (P = .01, 1-sided), respectively, for those 25 mm or less compared with those greater than 25 mm.
  • CONCLUSIONS: Lymph node status has a strong relationship to tumor diameter for non-small cell and small cell cancers.
  • The percentages of N0 M0 cases in screen-diagnosed lung cancers are much higher than previously reported in the Surveillance, Epidemiology, and End Results registry.
  • [MeSH-major] Lung Neoplasms / pathology. Mass Screening. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Small Cell / pathology. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476872.001).
  • [ISSN] 0003-9926
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Yano Y, Satoh H, Fukumoto K, Kumadaki I, Ichikawa T, Yamada K, Hagiwara K, Yano T: Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol. Int J Cancer; 2005 Jul 10;115(5):839-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol.
  • We estimated the possibility of T3E as a new anticancer agent against lung adenocarcinoma showing poor prognosis based on the mutation of ras gene.
  • T3E showed cytotoxicity against A549 cells, a human lung adenocarcinoma cell line with a ras gene mutation, in a dose-dependent manner (0-40 microM), whereas T3 and a redox-silent analogue of alpha-tocopherol (T), 6-O-carboxypropyl-alpha-tocopherol (TE), showed much less cytotoxicity in cells within 40 microM.
  • T3E cytotoxicity was based on the accumulation of cells in the G1-phase of the cell-cycle and the subsequent induction of apoptosis.
  • Similar to this event, 24-hr treatment of A549 cells with 40 microM T3E caused the inhibition of Ras farnesylation, and a marked decrease in the levels of cyclin D required for G1/S progression in the cell-cycle and Bcl-xL, a key anti-apoptotic molecule.
  • In conclusion, a redox-silent analogue of T3, T3E may be a new candidate as an anticancer agent against lung adenocarcinoma showing poor prognosis based on the mutation of ras genes.
  • [MeSH-major] Adenocarcinoma / pathology. Antioxidants / pharmacology. Lung Neoplasms / pathology. Tocotrienols / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Death. Cyclin D. Cyclins / metabolism. Humans. Oxidation-Reduction. Prognosis. Tumor Cells, Cultured. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15723336.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 6-O-carboxypropyl-alpha-tocotrienol; 0 / Antioxidants; 0 / Cyclin D; 0 / Cyclins; 0 / Tocotrienols; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


68. Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R, Nakamura Y: UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer; 2010 Jul 13;103(2):217-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UHRF1 is a novel diagnostic marker of lung cancer.
  • BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide.
  • As the sensitivity and specificity of current diagnostic markers are not perfect, we examined whether ubiquitin-like with PHD and ring finger domains 1 (UHRF1), which is overexpressed in various cancers but not yet examined in lung cancer in large scale, can be a novel diagnostic marker of lung cancer.
  • METHODS: Immunohistochemical analysis using surgical specimens obtained from 56 US and 322 Japanese patients with lung cancer was performed.
  • RESULTS: The UHRF1 was stained specifically in the nuclei of cancer cells, but not in the other cells.
  • The UHRF1 expression was observed in all histological types of lung cancer, especially in non-adenocarcinomas (non-ADCs), both in the US and Japanese cases.
  • In 322 Japanese non-small cell lung cancer (NSCLC) cases, UHRF1 expression was associated with the histological type (higher in non-ADCs; P<0.00001), gender (higher in male; P=0.00082), smoking (higher in smokers; P=0.00004), pT factor (higher in advanced stage; P=0.00010), and pN factor (higher in cancers with metastasis in regional lymph nodes; P=0.00018).
  • Although UHRF1 overexpression was associated with these malignant indicators, UHRF1 was detectable in half of lung cancer patients in an early pathological stage.
  • CONCLUSION: The UHRF1 is overexpressed in various types of lung cancer from early pathological stage.
  • Therefore, detection of UHRF1 expression in tissue specimens by immunohistochemistry can be useful for diagnosis of lung cancer in all pathological stages.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. CCAAT-Enhancer-Binding Proteins / analysis. Lung Neoplasms / diagnosis. Neoplasms, Squamous Cell / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11601-11 [18089789.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):908-12 [17994007.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(2):705-17 [17967883.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2008 Feb;56(2):43-53 [18297458.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):534-9 [18689853.001]
  • [Cites] Nature. 2008 Oct 9;455(7214):826-9 [18772888.001]
  • [Cites] Nature. 2008 Oct 9;455(7214):822-5 [18772889.001]
  • [Cites] Nature. 2008 Oct 9;455(7214):818-21 [18772891.001]
  • [Cites] Nucleic Acids Res. 2009 Feb;37(2):493-505 [19056828.001]
  • [Cites] Br J Cancer. 2009 Jul 7;101(1):98-105 [19491893.001]
  • [Cites] Br J Cancer. 2009 Nov 17;101(10):1782-91 [19809427.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Dec 18;390(3):523-8 [19800870.001]
  • [Cites] Breast Cancer Res Treat. 2010 Sep;123(2):359-73 [19943104.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):121-8 [10646863.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2192-205 [12687021.001]
  • [Cites] Respirology. 2003 Jun;8(2):163-7 [12753530.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):120-7 [12838312.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7601-10 [15361834.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8363-70 [15623614.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5638-46 [15994936.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1773-8 [16033098.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7102-10 [16103059.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Oct 31;140(1-2):25-33 [16084624.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1101-7 [16226110.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1454-63 [16285947.001]
  • [Cites] Mol Biol Cell. 2005 Dec;16(12):5621-9 [16195352.001]
  • [Cites] Jpn J Clin Oncol. 2006 May;36(5):309-24 [16735374.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):567-75 [16865272.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • (PMID = 20517312.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / UHRF1 protein, human
  • [Other-IDs] NLM/ PMC2906730
  •  go-up   go-down


69. Song M, Hu C, Xiao K: [The clinical analysis of 469 pulmonary carcinomatous cases diagnosed by bronchoscopy under the age of 40.]. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):410-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical analysis of 469 pulmonary carcinomatous cases diagnosed by bronchoscopy under the age of 40.].
  • BACKGROUND: In recent years, more and more young patients have been suffering from lung cancer, and these young patients do not always have good prognosis.
  • This article wants to study the relationship between the histopathology with gender, location and the sign of fibrobronchoscopy in lung cancer patients under the age of 40.
  • METHODS: The article analyzed retrospectively the fibrobronchoscopy data of 469 young lung cancer patients under the age of 40.
  • The most common histopathology was squamous cell carcinoma (33.0%), followed by adenocarcinoma (26.
  • %) and small cell carcinoma (20.5%).
  • The ratio of squamous cell carcinoma in male (40.7%) was more than in female (14.6%), and ratio of adenocarcinoma in female (43.1%) was more than in male (19.0%), it is obviously different on the distribution of cancer histopathology between male and female patients (P >0.05).
  • The location of lung carcinoma was more likely in the bilateral upper lobars and in the right lung, 81.4% had direct signs.
  • CONCLUSIONS: Lung cancer patients under the age of 40, squamous cell carcinoma is significantly more in male group, but adenocarcinoma is significantly more in female group.
  • This study suggests fibrobrochoscopy is an indispensable approach in the diagnosis of young lung cancer.
  • Paying more attention to the lung cancer of young patients and examining with fibrobronchoscopy will be found much helpful to early diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731944.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Lachkar S, Bota S, Nouvet G, Thiberville L: [Acute encephalopathy after infusion of paclitaxel]. Rev Mal Respir; 2006 Feb;23(1 Pt 1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Encéphalopathie aiguë après injection de paclitaxel.
  • CASE REPORT: We report a case of acute encephalopathy, occurring eight hours after infusion of Paclitaxel, in a patient treated for adenocarcinoma of the lung.
  • The diagnosis of encephalopathy secondary to Paclitaxel injection was reached after exclusion of other possible aetiologies.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604029.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 12
  •  go-up   go-down


71. Zang YS, Xiu QY, Fang Z, Li B, Xia TB: Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone. Oncologist; 2008 Jan;13(1):79-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone.
  • This case report details the sudden onset of severe dermatomyositis (DM) symptoms followed by rapid progression of adenocarcinoma of the lung and an obvious diminution of the primary tumor with the administration of lung cancer targeted drug therapy alone, followed by nearly complete disappearance of the DM symptoms, with no conspicuous improvement in the DM symptoms when using corticosteroids.
  • [MeSH-major] Adenocarcinoma / drug therapy. Dermatomyositis / drug therapy. Glucocorticoids / therapeutic use. Lung Neoplasms / drug therapy. Paraneoplastic Syndromes / drug therapy

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245014.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


72. Hasegawa Y, Tomita K, Watanabe M, Yamasaki A, Sano H, Hitsuda Y, Shimizu E: Dexamethasone inhibits phosphorylation of histone H3 at serine 10. Biochem Biophys Res Commun; 2005 Nov 4;336(4):1049-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we investigated the ability of dexamethasone (Dex) to inhibit p-Ser10 expression in response to tumor necrosis factor (TNF-alpha) in the human lung adenocarcinoma cell line A549 and the SV-40-transformed human airway epithelial cell line BEAS-2B.
  • Flow cytometric analysis at a single-cell level in A549 cells indicated that TNF-alpha treatment caused early induction of p-Ser10 at 15 min, which was inhibited significantly by pretreatment with 10(-5) M Dex.
  • [MeSH-minor] Cell Line, Transformed. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cytoplasmic Granules / drug effects. Cytoplasmic Granules / metabolism. Humans. Phosphorylation. RNA Polymerase II / metabolism. Tumor Necrosis Factor-alpha / pharmacology

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16165091.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Histones; 0 / Tumor Necrosis Factor-alpha; 452VLY9402 / Serine; 7S5I7G3JQL / Dexamethasone; EC 2.7.7.- / RNA Polymerase II
  •  go-up   go-down


73. Wu Z, Upadhyaya M, Zhu H, Qiao Z, Chen K, Miao F: Hepatoid adenocarcinoma: computed tomographic imaging findings with histopathologic correlation in 6 cases. J Comput Assist Tomogr; 2007 Nov-Dec;31(6):846-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma: computed tomographic imaging findings with histopathologic correlation in 6 cases.
  • OBJECTIVE: Hepatoid adenocarcinoma (HAC) is a special type of primary tumor with aberrant hepatocellular differentiation occurring in extrahepatic organs.
  • Two radiologists who were unaware of the final histological diagnosis reviewed all computed tomographic images retrospectively.
  • CONCLUSIONS: In an old patient with a large necrotic and moderately vascular tumor, the presence of distant metastases, regional lymphadenopathy, and characteristic increased serum alpha-fetoprotein level may suggest a diagnosis of HAC.
  • [MeSH-major] Adenocarcinoma / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Follow-Up Studies. Gastrectomy. Hemorrhage / pathology. Humans. Image Processing, Computer-Assisted / methods. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Lymph Nodes / pathology. Male. Middle Aged. Necrosis. Orchiectomy. Pneumonectomy. Retrospective Studies. Stomach Neoplasms / pathology. Stomach Neoplasms / radiography. Testicular Neoplasms / pathology. Testicular Neoplasms / radiography. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043368.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / alpha-Fetoproteins
  •  go-up   go-down


74. Sato T, Ito J, Shibuya H, Asano K, Watari T: Pulmonary adenosquamous carcinoma in a dog. J Vet Med A Physiol Pathol Clin Med; 2005 Dec;52(10):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenosquamous carcinoma in a dog.
  • A mass that developed in the lung of a 10-year-old mixed-breed dog was pathologically examined.
  • Histopathological examination showed papillary and tubular growth of glandular epithelium-like cells in some areas and growth of squamous cells arranged in nests in other areas, showing coexistence of adenocarcinoma and squamous cell carcinoma in a lung tumour.
  • Electron microscopically, the neoplastic cells of the adenocarcinoma component had features of glandular cells, with microvilli, numerous free ribosomes, large round secretory granules and intercellular desmosomes.
  • Non-keratinized squamous cells had tonofilaments and intercellular desmosomes.
  • These findings led to the diagnosis of primary adenosquamous carcinoma, which demonstrates phenotypic profiles characteristic of both epidermal keratinocytes and glandular epithelium.
  • [MeSH-major] Carcinoma, Adenosquamous / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300659.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Yoon MY, Song CS, Seo MH, Kim MJ, Oh TY, Jang UH, Kwag HJ, Kim HS, Lim SY, Lim SY, Lee SS: A case of metachronous metastasis to the breast from non-small cell lung carcinoma. Cancer Res Treat; 2010 Sep;42(3):172-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metachronous metastasis to the breast from non-small cell lung carcinoma.
  • We report here on a case of a 42-year-old female with metastasis of non-small cell lung cancer to the breast, and she is now being followed up on an outpatient basis.
  • In 2004, she presented with a solitary pulmonary nodule in the left lung, and this lesion had been noted to have gradually increased in size over time.
  • The final pathological diagnosis was adenocarcinoma, and the diagnosis was made by performing percutaneous needle aspiration and lobectomy of the left upper lobe.
  • Unfortunately, a nodule in the left breast was noted three years later, and metastatic non-small-cell lung cancer to the breast was diagnosed by excisional biopsy.
  • Making the correct diagnosis to distinguish a primary breast carcinoma from a metastatic one is important, because the therapeutic plan and outcome for these two types of cancer are quite different.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948923.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2953781
  • [Keywords] NOTNLM ; Adenocarcinoma / Metachronous breast metastasis / Non-small cell lung carcinoma
  •  go-up   go-down


81. Popescu I: [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention]. Pneumologia; 2008 Oct-Dec;57(4):201-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention].
  • [Transliterated title] Leziunile bronşice pre-neoplazice: posibilităţi de diagnostic şi chemo-prevenţie.
  • Early diagnosis of pulmonary cancer is crucial in the fight against this disease.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Biomarkers, Tumor / metabolism. Bronchoalveolar Lavage. Bronchoscopy / methods. Cetuximab. Early Diagnosis. Erlotinib Hydrochloride. Genes, p16. Humans. Mass Screening. Mutation. Positron-Emission Tomography. Predictive Value of Tests. Quinazolines / administration & dosage. Sensitivity and Specificity. Tomography, Optical Coherence. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186682.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; 0 / Tumor Suppressor Protein p53; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  • [Number-of-references] 48
  •  go-up   go-down


82. Tang F, Zhao LT, Jiang Y, Ba de N, Cui LX, He W: Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol Immunol; 2008 Jun;5(3):189-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that tumor nodule formation was retarded and tumor growth was inhibited in the subcutaneous tumor model of LA795 lung adenocarcinoma after treatment with rhIL-15, and the survival rate of T739 tumor-bearing mice treated with rhIL-15 was much higher than that of mice treated with either saline or with the same dose of rhIL-2.
  • In some rhIL-15 treated mice, the tumor cells inoculated subcutaneously were eradicated and there was no tumor formation even 138 days after tumor cell inoculation.
  • The tumor-free mice were rechallenged with live tumor cells and no tumor reoccurred in the following two months in all of these mice, indicating that long-lasting antitumor systemic immunity developed.
  • It was also shown that tumor recurrence and metastasis were inhibited markedly after treatment with rhIL-15, but not with the same dose of rhIL-2, in both subcutaneously and intravenously disseminated tumor models of LA795 lung adenocarcinoma.
  • Simultaneously, the CTL and NK cell activities of the splenocytes obtained from tumor-bearing mice that had been treated with either rhIL-15 or rhIL-2 were both markedly enhanced.
  • However, the enhancement of CTL and NK cell activities was more significant in rhIL-15 treated mice than that in rhIL-2 treated mice.
  • This suggests that the anti-tumor effect of rhIL-15 in vivo was achieved by enhancing the CTL and NK cell activities in tumor immune response.
  • [MeSH-major] Adenocarcinoma / drug therapy. Interleukin-15 / immunology. Interleukin-15 / therapeutic use. Neoplasm Metastasis / prevention & control. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Random Allocation. Recombinant Proteins / immunology. Recombinant Proteins / metabolism. Recombinant Proteins / therapeutic use

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582400.001).
  • [ISSN] 1672-7681
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-15; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ PMC4651289
  •  go-up   go-down


83. Heeger S: Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer. Recent Results Cancer Res; 2008;177:131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer.
  • The so-called "small molecule" tyrosine kinase inhibitor erlotinib has gained marketing authorization in the United States for advanced adenocarcinoma of the lung and for pancreatic cancer, whereas the antibody cetuximab is registered for metastatic colorectal cancer and cancers of the head and neck.
  • Ongoing studies are evaluating the impact of EGFR-targeting therapy in the treatment of locally advanced and metastatic pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084955.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 28
  •  go-up   go-down


84. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y: Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res; 2009 Aug 15;69(16):6694-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer.
  • Gene expression profile analysis of lung cancers revealed the transactivation of an immunoglobulin-like molecule Nectin-4 in the majority of non-small cell lung cancers (NSCLC).
  • A combined ELISA for both Nectin-4 and CEA increased sensitivity and classified 65.0% of lung adenocarcinomas as positive with false-positive rate of 4.6%.
  • The use of both Nectin-4 and CYFRA21-1 classified 68.3% of lung squamous cell carcinomas as positive with false-positive rate of 6.1%.
  • Treatment of lung cancer cells with small interfering RNAs against Nectin-4 suppressed its expression and cell growth.
  • Nectin-4 might play a significant role in lung carcinogenesis, and it should be a new candidate serum and tissue biomarker, as well as a therapeutic target.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Cell Adhesion Molecules / physiology. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy


85. Liu S, Cheng H, Yao S, Wang C, Han G, Li X, Liu C: The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. Ann Nucl Med; 2010 Aug;24(7):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features.
  • OBJECTIVE: The goal of our study was to demonstrate the clinical usefulness of positron emission tomography/computed tomography (PET/CT) for adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, through evaluating the relationship between the intrathoracic lymph node metastases and maximum standardized uptake value (SUVmax), tumor size of the primary tumor and the ratio of BAC component and analysing the correlation of SUVmax, tumor size and the ratio of BAC component.
  • Forty-five patients with focal peripheral lung adenocarcinoma with BAC features were included in this study and underwent the PET/CT scan.
  • The diagnosis of the lesion was made by surgical histopathology.
  • The maximum dimension of a tumor on pulmonary window setting images (pDmax, P = 0.373) had no significance.
  • CONCLUSIONS: PET/CT would be clinically useful for adenocarcinoma with BAC features, because SUVmax obtained by PET/CT can predict the incidence of intrathoracic lymph node metastases at preoperative stages and even for inoperable patients.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / complications. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614257.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS: HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon? J Radiat Res; 2010;51(3):257-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding a potential application of HDI as a radiosensitizer in the treatment of solid tumors, an important question is whether treatment efficacy would be influenced by intrinsic differences between cancer cells, such as different histologic origin and status of ATM or p53.
  • First we have observed the in vitro radiosensitization by Trichostatin A (TSA) on the broad spectrum of human tumor cell lines having different histologic origin such as HCT116 adenocarcinoma of colon, A549 adenocarcinoma of lung, HN-3 squamous cell carcinoma of head/neck, and HeLa squamous carcinoma of uterine cervix, using clonogenic assay.
  • Next, we have systematically assessed the radiosensitization on the cell lines having different ATM or p53 status.
  • We found that pretreatment of HDI consistently resulted in radiosensitization of all cell lines tested, though the sensitizer enhancement ratio of individual cell lines was variable.
  • The data presented here indicate that HDI enhances the radiation induced cell killing in the various cancer cells having intrinsic differences and may serve as a general strategy for enhancing tumor cell radiosensitivity.
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Radiation. Genes, p53. HeLa Cells. Humans. Hydroxamic Acids / pharmacology. Male. Radiation Tolerance. Radiation-Sensitizing Agents / pharmacology. Time Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505264.001).
  • [ISSN] 1349-9157
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Radiation-Sensitizing Agents; 3X2S926L3Z / trichostatin A
  •  go-up   go-down


87. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y: Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res; 2008 Dec 15;14(24):8213-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confirmation of gene expression-based prediction of survival in non-small cell lung cancer.
  • PURPOSE: It is a critical challenge to determine the risk of recurrence in early stage non-small cell lung cancer (NSCLC) patients.
  • EXPERIMENTAL DESIGN: Multiple published microarray data sets were used to evaluate our previously identified lung cancer prognostic gene signature.
  • Expression of the signature genes was further validated with real-time reverse transcription-PCR and Western blot assays of snap-frozen lung cancer tumor tissues.
  • The expression of the signature genes was validated with real-time reverse transcription-PCR analysis of lung cancer tumor specimens.
  • Protein expression of two signature genes, TAL2 and ILF3, was confirmed in lung adenocarcinoma tumors by using Western blot analysis.
  • These two biomarkers showed correlated mRNA and protein overexpression in lung cancer development and progression.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2000 Oct 20;80(2):192-202 [11074587.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):26-31 [11227069.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Genome Biol. 2003;4(4):R27 [12702208.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Aug;29(2):157-62 [12600827.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5360-70 [15064725.001]
  • [Cites] Science. 2004 Oct 22;306(5696):640-3 [15499008.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3875-84 [15492012.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7278-85 [16129846.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Science. 2006 May 26;312(5777):1165-8 [16728629.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54 [16740756.001]
  • [Cites] Exp Oncol. 2006 Jun;28(2):99-105 [16837898.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Mamm Genome. 2006 Sep;17(9):941-9 [16964442.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(2):229-35 [16932852.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 1:S5 [17430572.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2946-54 [17504995.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • (PMID = 19088038.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084953-050003; United States / NCRR NIH HHS / RR / P20 RR016440; United States / NCRR NIH HHS / RR / P20 RR16440-03; United States / NCI NIH HHS / CA / R01 CA060731; United States / NCI NIH HHS / CA / 5R01CA060731-13; United States / NLM NIH HHS / LM / R01 LM009500; United States / NLM NIH HHS / LM / LM009500-01A2; United States / NCI NIH HHS / CA / U19 CA084953-050003; United States / NCRR NIH HHS / RR / RR016440-08; United States / NLM NIH HHS / LM / R01 LM009500-01A2; United States / NCRR NIH HHS / RR / P20 RR016440-08; United States / NCI NIH HHS / CA / U19 CA084953; United States / NCI NIH HHS / CA / R01 CA154365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78586; NLM/ PMC2605664
  •  go-up   go-down


88. Endo S, Saito N, Hasegawa T, Sato Y, Sohara Y: Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery. Jpn J Thorac Cardiovasc Surg; 2005 Jul;53(7):369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery.
  • A 71-year-old man who had undergone surgery for stage II adenocarcinoma of the lung followed by adjuvant tegafur-uracil (UFT; 300 mg/day) therapy was admitted.
  • Multiple nodules were found in both lungs on chest radiographs obtained 1.5 years after the surgery.
  • Imaging characteristics of the nodules resembled those of pulmonary metastases.
  • Histologic assessment of a biopsy specimen obtained during thoracoscopic resection revealed pulmonary cryptococcosis.
  • Physicians need to be aware of the possibility of pulmonary cryptococcosis mimicking pulmonary metastases in patients treated with UFT after surgery for lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cryptococcosis / diagnosis. Lung Diseases, Fungal / diagnosis. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Male. Tegafur / therapeutic use. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1967 Oct;67(4):724-32 [6069972.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Mar;30(3):393-401 [1569717.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 1998 Dec;36(12 ):1038-42 [10064958.001]
  • [Cites] AJR Am J Roentgenol. 1984 May;142(5):893-6 [6609567.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):330-4 [12016357.001]
  • [Cites] Br J Radiol. 2002 Mar;75(891):275-8 [11932223.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Chest. 2003 Dec;124(6):2143-7 [14665493.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Jun;15(6):1915-20 [3132895.001]
  • (PMID = 16095237.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


89. Xu Y, Liu H, Chen J, Zhou Q: Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther; 2010 Apr 15;9(8):572-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non-small-cell lung cancer (NSCLC).
  • Interestingly, treatment with these small molecule, reversible EGFR-TKIs leads to more positive response rates in patients with adenocarcinoma, in females, Asians, and patients with no history of smoking.
  • However, despite the dramatic initial response to TKIs, most lung cancer patients relapse and subsequently become resistant to the drug, a process termed acquired resistance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404520.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


90. Devaux B, Rosenstingl S, Bardet M, Coldea L, Gatfosse M: [Abnormalities of hand skin]. Rev Med Interne; 2009 May;30(5):434-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Des anomalies de la peau des mains.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264380.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Huang J, Chen F, Wu Y, Yang J: [Expression and clinical significance of ADAM8 and CEA in serum of patients with non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Dec 20;11(6):789-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of ADAM8 and CEA in serum of patients with non-small cell lung cancer.].
  • BACKGROUND: Lung cancer is one of the most common cancers in the world, whose mortality is at the first place in all malignant tumors.
  • This study is to investigate the diagnostic value of ADAM8 and CEA in serum of non-small cell lung cancer patients.
  • RESULTS: The serum level of ADAM8 and CEA in group of NSCLC were both remarkably higher than those in lung benign lesions and normal controls (P <0.01), without significant difference between benign palmonary lesions and normal controls (P >0.05).
  • There was no significant difference between adenocarcinoma and squamous cell carcinoma in serum ADAM8 level (P >0.05).
  • The serum level of CEA in adenocarcinoma were significantly higher than that in squamous cell carcinoma (P <0.05).
  • CONCLUSIONS: The overexpression of ADAM8 in serum of NSCLC patients indicates that ADAM8 is related to the development of NSCLC; Combined detection of ADAM8 and CEA is helpful for the diagnosis of NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20797330.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Ntalli NG, Cottiglia F, Bueno CA, Alché LE, Leonti M, Vargiu S, Bifulco E, Menkissoglu-Spiroudi U, Caboni P: Cytotoxic tirucallane triterpenoids from Melia azedarach fruits. Molecules; 2010 Sep;15(9):5866-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the isolated compounds toward the human lung adenocarcinoma epithelial cell line A549 was determined, while no activity was observed against the phytonematode Meloidogyne incognita.
  • [MeSH-minor] Adenocarcinoma / pathology. Animals. Cell Line, Tumor. Epithelial Cells / drug effects. Fruit / chemistry. Humans. Lung Neoplasms / pathology. Molecular Structure. Plant Extracts / isolation & purification. Plant Extracts / toxicity. Tylenchoidea / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802401.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Plant Extracts; 0 / Triterpenes; 0 / tirucallane; Adenocarcinoma of lung
  •  go-up   go-down


93. Izquierdo-Garcia FM, Moreno-Mata N, Herranz-Aladro ML, Cañizares MA, Alvarez-Fernandez E: Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment. Histol Histopathol; 2010 10;25(10):1287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment.
  • Rhabdoid tumor, included in the WHO classification among large cell carcinomas of the lung, is an uncommon type of lung carcinoma with poor prognosis.
  • We report a series of 7 cases of lung carcinomas with rhabdoid component in 10% and 80% of the tumor.
  • The associated tumor was adenocarcinoma in 3 cases--one of them with focal micropapillary pattern--large cell carcinoma in 2 cases, squamous cell carcinoma in 1 case and pleomorphic carcinoma in 1 case.
  • Two adenocarcinomas showed a focal spindle cell component.
  • Alveolar trapping inside the tumor was present in 3 cases--a phenomenon not well studied in lung carcinomas and also not reported in tumors with rhabdoid component.
  • Five patients died because of the tumor within 2 to 31 months after diagnosis, one of myocardial infarction and only one is alive and disease free 123 months after the diagnosis.
  • In summary, we describe 7 new cases of this uncommon lung tumor with aggressive clinical course, associated with infrequent histological types in nonrhabdoid component and with alveolar trapping, a nondescribed finding.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Pulmonary Alveoli / pathology. Rhabdoid Tumor / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712013.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Metzelder SK, Reinke C, Walthers EM, Barth P, Vogelmeier C, Neubauer A, Bals R: ["Malignant" ARDS]. Internist (Berl); 2009 Oct;50(10):1272, 1274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the second patient, lung histology revealed an adenocarcinoma of the lung.
  • Beside solid cancers and lymphomas, acute and progressive forms of inflammatory, parenchymal lung diseases (such as acute interstitial pneumonitis, acute eosinophilic pneumonia, diffuse alveolar hemorrhagia, and acute hypersensitivity pneumonitis) can manifest with this picture.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Lung Diseases, Interstitial / complications. Lung Diseases, Interstitial / diagnosis. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Respiratory Distress Syndrome, Adult / diagnosis. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Crit Care. 1994 Mar;9(1):72-81 [8199655.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):415-24 [10862050.001]
  • [Cites] Chest. 2004 Apr;125(4):1530-5 [15078770.001]
  • [Cites] Thorax. 2002 May;57(5):452-8 [11978926.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304 [11790668.001]
  • (PMID = 19562262.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Cao X, Bennett RL, May WS: c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem; 2008 May 23;283(21):14490-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To test whether c-Myc and caspase-2 cooperate to activate Bax and thereby mediate intrinsic apoptosis, small interfering RNA was used to efficiently knock down the expression of c-Myc, caspase-2, and Apaf-1, an activating component in the apoptosome, in two human cancer cell lines, lung adenocarcinoma A-549 and osteosarcoma U2-OS cells.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 May 2;272(18):11671-3 [9115213.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):10890-5 [16464852.001]
  • [Cites] Science. 1997 Jul 18;277(5324):370-2 [9219694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11357-62 [9326614.001]
  • [Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]
  • [Cites] Cell. 1997 Nov 28;91(5):627-37 [9393856.001]
  • [Cites] Nature. 1998 Jan 29;391(6666):496-9 [9461218.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1675-87 [9501089.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):3878-85 [9670005.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):207-15 [9763432.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):217-24 [9763433.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34157-63 [9852076.001]
  • [Cites] J Biol Chem. 1999 Jan 22;274(4):2225-33 [9890985.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):281-92 [9922454.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8309-15 [10075737.001]
  • [Cites] EMBO J. 1999 May 4;18(9):2330-41 [10228148.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1367-81 [10364155.001]
  • [Cites] Biochem J. 2000 Jan 15;345 Pt 2:271-8 [10620504.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6318-25 [11103792.001]
  • [Cites] Cell. 2000 Nov 10;103(4):645-54 [11106734.001]
  • [Cites] J Cell Biol. 2001 Feb 5;152(3):483-90 [11157976.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):11615-23 [11136736.001]
  • [Cites] J Cell Biol. 2001 Apr 16;153(2):319-28 [11309413.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4725-36 [11416148.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6627-36 [11726499.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6158-69 [12167710.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29803-9 [12065594.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1352-4 [12193789.001]
  • [Cites] J Cell Biol. 2002 Dec 9;159(5):739-45 [12460989.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):2058-65 [12426317.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):352-7 [12652309.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2605-14 [12816867.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):14964-9 [1869534.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):269-75 [7846125.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):353-7 [9002522.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22532-8 [10428830.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1021-5 [10514382.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5113-8 [9144199.001]
  • (PMID = 18375382.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL054083; United States / NCI NIH HHS / CA / CA 44649
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / BAX protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; 0 / bcl-2-Associated X Protein; 9007-43-6 / Cytochromes c; EC 3.4.22.- / CASP2 protein, human; EC 3.4.22.- / Caspase 2; EC 3.4.22.- / Cysteine Endopeptidases; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2386933
  •  go-up   go-down


96. Parra ER, Park JY, Saito DM, Takagaki TY, Rodrigues OR, Capelozzi VL: Prognostic index expression of cyclin-D1, cerbB-2 and VEGF: metastases vs corresponding primary cancers and metastatic vs non-metastatic adenocarcinomas. Histol Histopathol; 2008 08;23(8):987-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic index expression of cyclin-D1, cerbB-2 and VEGF: metastases vs corresponding primary cancers and metastatic vs non-metastatic adenocarcinomas.
  • The prognostic relevance of different molecular markers in lung cancer is a crucial issue still worth investigating, and the specimens collected and analyzed represent a valuable source of material.
  • Cyclin-D1, c-erbB-2 and vascular endothelial growth factor (VEGF) have shown to be promising as prognosticators in human cancer.
  • In this study, we sought to examine the importance of Cyclin-D1, c-erbB-2 and VEGF, and to study the quantitative relationship among these factors and disease progression in metastases vs corresponding primary cancer, and metastatic vs non metastatic cancers.
  • MATERIAL AND METHODS: We used immunohistochemistry and morphometric analysis to evaluate the amount of tumour staining for Cyclin-D1, c-erbB-2 and VEGF in 52 patients with surgically excised adenocarcinoma of the lung, and the outcome for our study was survival time until death from hematogenic metastases.
  • Non-metastatic cancers also presented significantly lower Cyclin-D1 and c-erbB-2 expression than metastatic cancers (p<0.01 and p<0.01, respectively).
  • Equally significant was the difference between higher c-erbB-2 expression by metastatic cancers compared to non-metastatic cancers (p=0.02).
  • CONCLUSION: Different tumour cell profiles in metastases, corresponding primary cancers, and non-metastatic cancers were found, thus suggesting that different cell clones control the invasive and non-invasive behaviour of the cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclins / metabolism. Lung Neoplasms / metabolism. Receptor, ErbB-2 / metabolism. Vascular Endothelial Growth Factor A / metabolism


97. Kim Y, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ: Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res; 2009 May;29(5):1817-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung.
  • BACKGROUND: The frequency of epithelial cell adhesion molecule (EpCAM) expression was investigated in non-small cell lung cancer (NSCLC) cells and human tissues, and its clinicopathological significance in adenocarcinoma of the lung was evaluated.
  • EpCAM protein expression was evaluated in 234 adenocarcinoma tissues using immunohistochemistry.
  • EpCAM overexpression was detected in 120/234 (51.3%) surgically resected adenocarcinoma tissues.
  • EpCAM overexpression occurred significantly more frequently in adenocarcinoma than in bronchioloalveolar carcinoma (p=0.02).
  • CONCLUSION: These findings suggest EpCAM plays a role in the carcinogenesis of adenocarcinoma of the lung and might provide a promising molecule for targeted therapy in NSCLC.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Cell Adhesion Molecules / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Primers. Flow Cytometry. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443410.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human
  •  go-up   go-down


98. Aokage K, Ishii G, Yoshida J, Hishida T, Nishimura M, Nagai K, Ochiai A: Histological progression of small intrapulmonary metastatic tumor from primary lung adenocarcinoma. Pathol Int; 2010 Dec;60(12):765-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological progression of small intrapulmonary metastatic tumor from primary lung adenocarcinoma.
  • Histological typing based on the World Health Organization classification (bronchioloalveolar carcinoma, acinar, papillary, and solid subtype) was used to evaluate 234 metastases from the primary lung adenocarcinomas of 139 patients.
  • These findings suggest that implanted cancer cells display lepidic growth in the early metastatic phase and recapitulate the morphological heterogeneity of the original tumor as the metastasis enlarges.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 21091834.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


99. Ikeda S, Inagaki M, Takabe K, Kumagai J, Suzuki K: Rapid detection of matrix metalloproteinase-7 and carcinoembryonic antigen mRNA expression in intraoperative pleural lavage samples using the reverse transcriptase loop-mediated isothermal amplification method. Acta Cytol; 2009 May-Jun;53(3):283-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To detect the RNA of the tumor origin in intraoperative pleural lavage accurately by examining using rapid nucleic acid amplification method because patients with lung cancer often have recurrence detected by a cytologic examination of cancer cells in intraoperative pleural lavage.
  • STUDY DESIGN: We used reverse transcriptase loop-mediated isothermal amplification (RT-LAMP), which enables rapid gene amplification, and examined the expression of matrix metalloproteinase-7 (MMP-7) and carcinoembryonic antigen (CEA) mRNA in intraoperative pleural lavage samples obtained from 79 consecutive surgical patients with lung adenocarcinoma.
  • RESULTS: MMP-7 mRNA was detected in cancer tissues from 76 (96%) of those cases, while it was also detected in the intraoperative pleural lavage samples of 23 (30%) of those 76 cases.
  • In addition, CEA mRNA was detected in cancer tissues from 55 (70%) cases and in 8 (15%) of the lavage samples.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cytodiagnosis / methods. Cytodiagnosis / trends. Female. Gene Expression. Humans. Intraoperative Care. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Lung Neoplasms / surgery. Male. Middle Aged. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2009 May-Jun;53(3):245-6 [19534261.001]
  • (PMID = 19534268.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


100. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • RESULTS: Coexpression of cytokeratins and vimentin was found in 63.9% of MM cases and cell-membrane reactions with EMA were seen in 58.9%.
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • Differentiation of MM from non-small cell carcinomas: Among the antibodies used in the study, anti-HBME1 had the highest sensitivity (76.7%) but lowest specificity (77.4%).
  • CONCLUSION: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down






Advertisement